<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MITOXANTRONE HYDROCHLORIDE- mitoxantrone hydrochloride injection, solution </strong><br>Pfizer Laboratories Div Pfizer Inc.<br></p></div>
<h1>Mitoxantrone Injection USP (Concentrate)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="ID35"></a><a name="section-1"></a><p></p>
<h1>BOXED WARNING</h1>
<p class="First"><a name="ID36"></a>MitoXANTRONE Injection should be administered under the supervision of a physician experienced in the use of cytotoxic chemotherapy agents. </p>
<p>MitoXANTRONE Injection should be given slowly into a freely flowing intravenous infusion. It must <span class="Italics">never</span> be given subcutaneously, intramuscularly, or intra-arterially. Severe local tissue damage may occur if there is <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> during administration. (See <span class="Bold"><a href="#ID124">ADVERSE REACTIONS, General,Cutaneous</a></span>  and <span class="Bold"><a href="#ID153">DOSAGE AND ADMINISTRATION, Preparation and Administration Precautions</a>). </span></p>
<p>NOT FOR INTRATHECAL USE. Severe injury with permanent sequelae can result from intrathecal administration. (See <span class="Bold"><a href="#ID81">WARNINGS, General</a></span>) </p>
<p>Except for the treatment of acute nonlymphocytic <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>, MitoXANTRONE Injection therapy generally should not be given to patients with baseline neutrophil counts of less than 1,500 cells/mm<span class="Sup">3</span>. In order to monitor the occurrence of bone marrow suppression, primarily <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, which may be severe and result in <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving MitoXANTRONE Injection. </p>
<p>Cardiotoxicity: </p>
<p><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> (CHF), potentially fatal, may occur either during therapy with MitoXANTRONE Injection or months to years after termination of therapy. Cardiotoxicity risk increases with cumulative MitoXANTRONE Injection dose and may occur whether or not cardiac risk factors are present. Presence or history of cardiovascular disease, radiotherapy to the mediastinal/pericardial area, previous therapy with other anthracyclines or anthracenediones, or use of other cardiotoxic drugs may increase this risk. In cancer patients, the risk of symptomatic CHF was estimated to be 2.6% for patients receiving up to a cumulative dose of 140 mg/m<span class="Sup">2</span>. To mitigate the cardiotoxicity risk with MitoXANTRONE Injection, prescribers should consider the following: </p>
<ul class="Disc"><li>  All Patients: </li></ul>
<ol>
<li>All patients should be assessed for cardiac signs and symptoms by history, physical examination, and ECG prior to start of MitoXANTRONE Injection therapy. </li>
<li>All patients should have baseline quantitative evaluation of left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> (LVEF) using appropriate methodology (ex. Echocardiogram, multi-gated radionuclide angiography (MUGA), MRI, etc.). </li>
</ol>
<ul class="Disc"><li>  <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">Multiple Sclerosis</span> Patients: </li></ul>
<ol>
<li>MS patients with a baseline LVEF below the lower limit of normal should not be treated with Mitoxantrone Injection. </li>
<li>MS patients should be assessed for cardiac signs and symptoms by history, physical examination and ECG prior to each dose. </li>
<li>MS patients should undergo quantitative reevaluation of LVEF prior to each dose using the same methodology that was used to assess baseline LVEF. Additional doses of MitoXANTRONE Injection should not be administered to <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> patients who have experienced either a drop in LVEF to below the lower limit of normal or a clinically significant reduction in LVEF during MitoXANTRONE Injection therapy. </li>
<li>MS patients should not receive a cumulative MitoXANTRONE Injection dose greater than 140 mg/m<span class="Sup">2</span>. </li>
<li>MS patients should undergo yearly quantitative LVEF evaluation after stopping MitoXANTRONE Injection to monitor for late occurring cardiotoxicity. </li>
</ol>
<p><a name="ID41"></a>Secondary <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span>: </p>
<p>MitoXANTRONE Injection therapy in patients with MS and in patients with cancer increases the risk of developing secondary <span class="product-label-link" type="condition" conceptid="140352" conceptname="Acute myeloid leukemia, disease">acute myeloid leukemia</span>.</p>
<p>For additional information, see <span class="Bold"><a href="#ID79">WARNINGS</a></span> and <span class="Bold"><a href="#ID143">DOSAGE AND ADMINISTRATION</a>.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID42"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><a name="ID43"></a>MitoXANTRONE Injection USP (Concentrate) is a synthetic antineoplastic anthracenedione for intravenous use. The molecular formula is C<span class="Sub">22</span>H<span class="Sub">28</span>N<span class="Sub">4</span>O<span class="Sub">6</span>•2HCl and the molecular weight is 517.41. It is supplied as a concentrate that MUST BE DILUTED PRIOR TO INJECTION. The concentrate is a sterile, nonpyrogenic, dark blue aqueous solution containing mitoxantrone hydrochloride equivalent to 2 mg/mL mitoxantrone free base, with sodium chloride (0.80% w/v), sodium acetate (0.005% w/v), Sodium Metabisulphite (0.01% w/v) and acetic acid (0.046% w/v) as inactive ingredients. The solution has a pH of 3.0 to 4.5 and contains 0.14 mEq of sodium per mL. The product does not contain preservatives. The chemical name is 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione dihydrochloride and the structural formula is:</p>
<div class="Figure">
<img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c101cb05-faaa-44cb-9666-c8214628c844&amp;name=mitoxan-inj-pfizer-figure-01.jpg"><p class="MultiMediaCaption">Image</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID45"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID46"></a><a name="section-2.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First"><a name="ID47"></a>Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. It has a cytocidal effect on both proliferating and nonproliferating cultured human cells, suggesting lack of cell cycle phase specificity. </p>
<p>MitoXANTRONE Injection has been shown <span class="Italics">in vitro</span> to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFα, and IL-2. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID48"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First"><a name="ID49"></a>Pharmacokinetics of mitoxantrone in patients following a single intravenous administration of MitoXANTRONE Injection can be characterized by a three-compartment model. The mean alpha half-life of mitoxantrone is 6 to 12 minutes, the mean beta half-life is 1.1 to 3.1 hours and the mean gamma (terminal or elimination) half-life is 23 to 215 hours (median approximately 75 hours). Pharmacokinetic studies have not been performed in humans receiving multiple daily dosing. Distribution to tissues is extensive: steady-state volume of distribution exceeds 1,000 L/m<span class="Sup">2</span>. Tissue concentrations of mitoxantrone appear to exceed those in the blood during the terminal elimination phase. In the healthy monkey, distribution to brain, spinal cord, eye, and spinal fluid is low. </p>
<p>In patients administered 15 to 90 mg/m<span class="Sup">2 </span>of MitoXANTRONE Injection intravenously, there is a linear relationship between dose and the area under the concentration-time curve (AUC). </p>
<p>Mitoxantrone is 78% bound to plasma proteins in the observed concentration range of 26 to 455 ng/mL. This binding is independent of concentration and is not affected by the presence of phenytoin, doxorubicin, methotrexate, prednisone, prednisolone, heparin, or aspirin. </p>
</div>
<div class="Section">
<a name="ID50"></a><a name="section-2.3"></a><p></p>
<h2>Metabolism and Elimination</h2>
<p class="First"><a name="ID51"></a>Mitoxantrone is excreted in urine and feces as either unchanged drug or as inactive metabolites. In human studies, 11% and 25% of the dose were recovered in urine and feces, respectively, as either parent drug or metabolite during the 5-day period following drug administration. Of the material recovered in urine, 65% was unchanged drug. </p>
<p>The remaining 35% was composed of monocarboxylic and dicarboxylic acid derivatives and their glucuronide conjugates. The pathways leading to the metabolism of MitoXANTRONE Injection have not been elucidated. </p>
</div>
<div class="Section">
<a name="ID52"></a><a name="section-2.4"></a><p></p>
<h2>Special Populations</h2>
<div class="Section">
<a name="ID53"></a><a name="section-2.4.1"></a><p></p>
<h3>Gender</h3>
<p class="First"><a name="ID54"></a>The effect of gender on mitoxantrone pharmacokinetics is unknown. </p>
</div>
<div class="Section">
<a name="ID55"></a><a name="section-2.4.2"></a><p></p>
<h3>Geriatric</h3>
<p class="First"><a name="ID56"></a>In elderly patients with breast cancer, the systemic mitoxantrone clearance was 21.3 L/hr/m<span class="Sup">2</span>, compared with 28.3 L/hr/m<span class="Sup">2 </span>and 16.2 L/hr/m<span class="Sup">2 </span>for non-elderly patients with nasopharyngeal carcinoma and <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">malignant lymphoma</span>, respectively. </p>
</div>
<div class="Section">
<a name="ID57"></a><a name="section-2.4.3"></a><p></p>
<h3>Pediatric</h3>
<p class="First"><a name="ID58"></a>Mitoxantrone pharmacokinetics in the pediatric population are unknown. </p>
</div>
<div class="Section">
<a name="ID59"></a><a name="section-2.4.4"></a><p></p>
<h3>Race</h3>
<p class="First"><a name="ID60"></a>The effect of race on mitoxantrone pharmacokinetics is unknown. </p>
</div>
<div class="Section">
<a name="ID61"></a><a name="section-2.4.5"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h3>
<p class="First"><a name="ID62"></a>Mitoxantrone pharmacokinetics in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> are unknown. </p>
</div>
<div class="Section">
<a name="ID63"></a><a name="section-2.4.6"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h3>
<p class="First"><a name="ID64"></a>Mitoxantrone clearance is reduced by <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Patients with severe hepatic dysfunction (bilirubin &gt; 3.4 mg/dL) have an AUC more than three times greater than that of patients with normal hepatic function receiving the same dose. Patients with <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> who have <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should ordinarily not be treated with MitoXANTRONE Injection. Other patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should be treated with caution and dosage adjustment may be required. </p>
</div>
</div>
<div class="Section">
<a name="ID65"></a><a name="section-2.5"></a><p></p>
<h2>Drug Interactions.</h2>
<p class="First"><a name="ID66"></a><span class="Bold"><span class="Italics">In vitro</span> drug interaction studies have demonstrated that mitoxantrone did not inhibit CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 across a broad concentration range. The results of <span class="Italics">in vitro</span> induction studies are inconclusive, but suggest that mitoxantrone may be a weak inducer of CYP450 2E1 activity. </span></p>
<p>Pharmacokinetic studies of the interaction of MitoXANTRONE Injection with concomitantly administered medications in humans have not been performed. The pathways leading to the metabolism of MitoXANTRONE Injection have not been elucidated. To date, post-marketing experience has not revealed any significant drug interactions in patients who have received MitoXANTRONE Injection for treatment of cancer. Information on drug interactions in patients with <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> is limited. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID67"></a><a name="section-2.6"></a><p></p>
<p class="First"><a name="ID68"></a><span class="Bold">CLINICAL TRIALS</span></p>
</div>
<div class="Section">
<a name="ID69"></a><a name="section-2.7"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">Multiple Sclerosis</span></h2>
<p class="First"><a name="ID70"></a>The safety and efficacy of MitoXANTRONE Injection in <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> were assessed in two randomized, multicenter clinical studies. </p>
<p>One randomized, controlled study (Study 1) was conducted in patients with secondary progressive or progressive relapsing <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>. Patients in this study demonstrated significant neurological <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> based on the Kurtzke Expanded <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">Disability</span> Status Scale (EDSS). The EDSS is an ordinal scale with 0.5 point increments ranging from 0.0 to 10.0 (increasing score indicates worsening) and based largely on ambulatory impairment in its middle range (EDSS 4.5 to 7.5 points). Patients in this study had experienced a mean deterioration in EDSS of about 1.6 points over the 18 months prior to enrollment. </p>
<p>Patients were randomized to receive placebo, 5 mg/m<span class="Sup">2 </span>MitoXANTRONE Injection, or 12 mg/m<span class="Sup">2 </span>MitoXANTRONE Injection administered IV every 3 months for 2 years. High-dose methylprednisolone was administered to treat relapses. The intent to treat analysis cohort consisted of 188 patients; 149 completed the 2-year study. Patients were evaluated every 3 months, and clinical outcome was determined after 24 months. In addition, a subset of patients was assessed with magnetic resonance imaging (MRI) at baseline, Month 12, and Month 24. Neurologic assessments and MRI reviews were performed by evaluators blinded to study drug and clinical outcome, although the diagnosis of relapse and the decision to treat relapses with steroids were made by unblinded treating physicians. A multivariate analysis of five clinical variables (EDSS, Ambulation Index [AI], number of relapses requiring treatment with steroids, months to first relapse needing treatment with steroids, and Standard Neurological Status [SNS]) was used to determine primary efficacy. The AI is an ordinal scale ranging from 0 to 9 in one point increments to define progressive ambulatory impairment. The SNS provides an overall measure of neurologic impairment and <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>, with scores ranging from 0 (normal neurologic examination) to 99 (worst possible score). </p>
<p>Results of Study 1 are summarized in Table 1. </p>
<p>. </p>
<a name="ID161"></a><table width="100%">
<caption><span>Table 1 - Efficacy Results at Month 24 - Study 1</span></caption>
<col width="23%">
<col width="16%">
<col width="22%">
<col width="16%">
<col width="23%">
<tfoot>
<tr class="First"><td align="left" colspan="5"><p class="First Footnote">NR = not reached within 24 months; MRI = magnetic resonance imaging. <br></p></td></tr>
<tr><td align="left" colspan="5"><p class="First Footnote"><span class="Sup">*</span> Wei-Lachin test. <br></p></td></tr>
<tr><td align="left" colspan="5"><p class="First Footnote"><span class="Sup">*</span><span class="Sup">*</span><span class="Sup"></span>Month 24 value minus baseline. <br></p></td></tr>
<tr class="Last"><td align="left" colspan="5"><p class="First Footnote"><span class="Sup">‡</span><span class="Sup"></span>A subset of 110 patients was selected for MRI analysis. MRI results were not available for all patients at all time points<br></p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" valign="middle"><span class="Bold"><br></span></td>
<td class="Toprule" align="center" valign="middle"><span class="Bold"><br></span></td>
<td class="Botrule Toprule" align="center" valign="middle"><span class="Bold"><br></span></td>
<td class="Botrule Toprule" align="center" valign="middle">
<span class="Bold">Treatment </span><span class="Bold">Groups</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="middle">
<span class="Bold">p</span><span class="Bold">-</span><span class="Bold">value</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td align="left" colspan="1" valign="bottom"><span class="Bold"><br></span></td>
<td align="left" colspan="1" valign="top"><br></td>
<td class="Botrule Toprule" align="center" colspan="2" valign="top">
<span class="Bold">MitoXANTRONE </span><span class="Bold"><br></span><span class="Bold">Injection</span><br>
</td>
<td class="Toprule" align="center" colspan="1" valign="top">
<span class="Bold">Placebo </span><span class="Bold">vs </span><span class="Bold"><br></span><span class="Bold">12 </span><span class="Bold">mg</span><span class="Bold">/</span><span class="Bold">m<span class="Sup">2</span></span><br>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="bottom">
<span class="Bold">Primary </span><span class="Bold">Endpoints</span><br>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">Placebo</span><span class="Bold"><br></span><span class="Bold">(</span><span class="Bold">N</span><span class="Bold">=</span><span class="Bold">64</span><span class="Bold">)</span><br>
</td>
<td class="Botrule Toprule" align="center" valign="middle">
<span class="Bold">5 </span><span class="Bold">mg</span><span class="Bold">/</span><span class="Bold">m<span class="Sup">2</span></span><span class="Bold"><br></span><span class="Bold">(</span><span class="Bold">N </span><span class="Bold">=</span><span class="Bold">64</span><span class="Bold">)</span><br>
</td>
<td class="Botrule Toprule" align="center" valign="middle">
<span class="Bold">12 </span><span class="Bold">mg</span><span class="Bold">/</span><span class="Bold">m<span class="Sup">2</span></span><span class="Bold"><br></span><span class="Bold">(</span><span class="Bold">N </span><span class="Bold">=</span><span class="Bold">60</span><span class="Bold">)</span><br>
</td>
<td class="Botrule" align="center" valign="top">
<span class="Bold">MitoXANTRONE</span><span class="Bold"><br></span><span class="Bold">Injection</span><br>
</td>
</tr>
<tr>
<td class="Toprule" align="left" valign="bottom">Primary efficacy multivariate analysis<span class="Sup">*</span><br>
</td>
<td class="Toprule" align="center" valign="middle">-<br>
</td>
<td class="Toprule" align="center" valign="middle">-<br>
</td>
<td class="Toprule" align="center" valign="middle">-<br>
</td>
<td class="Toprule" align="center" valign="middle">&lt;0.0001<br>
</td>
</tr>
<tr>
<td align="left" valign="bottom"><br></td>
<td align="center" valign="middle"><br></td>
<td align="center" valign="middle"><br></td>
<td align="center" valign="middle"><br></td>
<td align="center" valign="middle"><br></td>
</tr>
<tr>
<td align="left" valign="bottom">EDSS change<span class="Sup">*</span><span class="Sup">*</span>(mean)<span class="Bold"><br></span>
</td>
<td align="center" valign="middle">0.23<br>
</td>
<td align="center" valign="middle">-0.23<br>
</td>
<td align="center" valign="middle">-0.13<br>
</td>
<td align="center" valign="middle">0.0194<br>
</td>
</tr>
<tr>
<td align="left" valign="bottom">Ambulation Index change<span class="Sup">*</span><span class="Sup">*</span>(mean)<br>
</td>
<td align="center" valign="middle">0.77<br>
</td>
<td align="center" valign="middle">0.41<br>
</td>
<td align="center" valign="middle">0.30<br>
</td>
<td align="center" valign="middle">0.0306<br>
</td>
</tr>
<tr>
<td align="left" valign="bottom">Mean number of relapses per patient requiring<br>
</td>
<td align="center" valign="middle">1.20<br>
</td>
<td align="center" valign="middle">0.73<br>
</td>
<td align="center" valign="middle">0.40<br>
</td>
<td align="center" valign="middle">0.0002<br>
</td>
</tr>
<tr>
<td align="left" valign="bottom">corticosteroid treatment(adjusted for discontinuation)<span class="Bold"><br></span>
</td>
<td align="center" valign="middle"><br></td>
<td align="center" valign="middle"><br></td>
<td align="center" valign="middle"><br></td>
<td align="center" valign="middle"><br></td>
</tr>
<tr>
<td align="left" valign="bottom">Months to first relapse requiring corticosteroid treatment (median [1<span class="Sup">s</span><span class="Sup">t</span> quartile])<br>
</td>
<td align="center" valign="middle">14.2 [6.7]<br>
</td>
<td align="center" valign="middle">NR[6.9]<br>
</td>
<td align="center" valign="middle">NR [20.4]<br>
</td>
<td align="center" valign="middle">0.0004<br>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="bottom">Standard Neurological Status change<span class="Sup">*</span><span class="Sup">*</span> (mean)<br>
</td>
<td class="Botrule" align="center" valign="middle">0.77<br>
</td>
<td class="Botrule" align="center" valign="middle">-0.38<br>
</td>
<td class="Botrule" align="center" valign="middle">-1.07<br>
</td>
<td class="Botrule" align="center" valign="middle">0.0269<br>
</td>
</tr>
<tr>
<td class="Botrule Toprule" align="left" valign="bottom">
<span class="Bold">MRI </span><span class="Sup">‡</span><br>
</td>
<td class="Botrule Toprule" align="center" valign="middle"><br></td>
<td class="Botrule Toprule" align="center" valign="middle"><br></td>
<td class="Botrule Toprule" align="center" valign="middle"><br></td>
<td class="Botrule Toprule" align="center" valign="middle"><br></td>
</tr>
<tr>
<td class="Toprule" align="left" valign="bottom"><span class="Bold"><br></span></td>
<td class="Toprule" align="center" valign="middle">  5/32 (16%)<br>
</td>
<td class="Toprule" align="center" valign="middle">    4/37 (11%)<br>
</td>
<td class="Toprule" align="center" valign="middle">0/31<br>
</td>
<td class="Toprule" align="center" valign="middle">0.022<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="bottom">-Change in number of T2-weighted lesions, mean (n)<span class="Sup">*</span><span class="Sup">*</span><br>
</td>
<td class="Botrule" align="center" valign="middle">
<br>1.94 (32)<br>
</td>
<td class="Botrule" align="center" valign="middle">0.68 (34)<br>
</td>
<td class="Botrule" align="center" valign="middle">0.29 (28)<br>
</td>
<td class="Botrule" align="center" valign="middle">0.027<br>
</td>
</tr>
</tbody>
</table>
<p><a name="ID162"></a>A second randomized, controlled study (Study 2) evaluated MitoXANTRONE Injection in combination with methylprednisolone (MP) and was conducted in patients with secondary progressive or worsening relapsing-remitting <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> who had residual neurological deficit between relapses. All patients had experienced at least two relapses with sequelae or neurological deterioration within the previous 12 months. The average deterioration in EDSS was 2.2 points during the previous 12 months. During the screening period, patients were treated with two monthly doses of 1 g of IV MP and underwent monthly MRI scans. Only patients who developed at least one new Gd enhancing MRI lesion during the 2-month screening period were eligible for randomization. A total of 42 evaluable patients received monthly treatments of 1 g of IV MP alone (n = 21) or ~12 mg/m<span class="Sup">2 </span>of IV MitoXANTRONE Injection plus 1 g of IV MP (n = 21) (MIT + MP) for 6 months. Patients were evaluated monthly, and study outcome was determined after 6 months. The primary measure of effectiveness in this study was a comparison of the proportion of patients in each treatment group who developed no new Gd-enhancing MRI lesions at 6 months; these MRIs were assessed by a blinded panel. Additional outcomes were measured, including EDSS and number of relapses, but all clinical measures in this trial were assessed by an unblinded treating physician. Five patients, all in the MP alone arm, failed to complete the study due to lack of efficacy. </p>
<p>The results of this trial are displayed in Table 2. </p>
<a name="ID163"></a><table width="100%">
<caption><span>Table 2- Efficacy Results - Study 2</span></caption>
<col width="46%">
<col width="19%">
<col width="22%">
<col width="13%">
<tfoot>
<tr class="First"><td align="left" colspan="4"><p class="First Footnote"> MP = methylprednisolone; MIT + MP = MitoXANTRONE Injection plus methylprednisolone <br></p></td></tr>
<tr class="Last"><td align="left" colspan="4"><p class="First Footnote">* Results at Month 6, not including data for 5 withdrawals in the MP alone group. <br></p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="top"><br></td>
<td class="Toprule" align="center" valign="top">
<span class="Bold">MP </span><span class="Bold">alone</span><br>
</td>
<td class="Toprule" align="center" valign="top">
<span class="Bold">MIT </span><span class="Bold">+ </span><span class="Bold">MP</span><br>
</td>
<td class="Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">
<span class="Bold">Primary </span><span class="Bold">Endpoint</span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" valign="top">
<span class="Bold">(</span><span class="Bold">N </span><span class="Bold">= </span><span class="Bold">21</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" valign="top">
<span class="Bold">(</span><span class="Bold">N </span><span class="Bold">= </span><span class="Bold">21</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" valign="top">
<span class="Bold">p</span><span class="Bold">-</span><span class="Bold">value</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Toprule" align="left" valign="top">Patients (%) without new Gd-enhancing lesions on MRIs (primary endpoint)<span class="Sup">*</span><span class="Sup"> </span><br>
</td>
<td class="Toprule" align="center" valign="middle">5 (31%)<br>
</td>
<td class="Toprule" align="center" valign="middle">19 (90%)<br>
</td>
<td class="Toprule" align="center" valign="middle">0.001<br>
</td>
</tr>
<tr>
<td align="left" valign="top"><br></td>
<td align="left" valign="top"><br></td>
<td align="left" valign="top"><br></td>
<td align="left" valign="top"><br></td>
</tr>
<tr>
<td align="left" valign="middle">EDSS change (Month 6 minus baseline)<span class="Sup">*</span> (mean)<br>
</td>
<td align="center" valign="top">-0.1<br>
</td>
<td align="center" valign="top">-1.1<br>
</td>
<td align="center" valign="top">0.013<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Annualized relapse rate (mean per patient)<br>
</td>
<td align="center" valign="top">3.0<br>
</td>
<td align="center" valign="top">0.7<br>
</td>
<td align="center" valign="top">0.003<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="middle">Patients (%) without relapses<br>
</td>
<td class="Botrule" align="center" valign="top">7 (33%)<br>
</td>
<td class="Botrule" align="center" valign="top">14 (67%)<br>
</td>
<td class="Botrule" align="center" valign="top">0.031<br>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section">
<a name="ID71"></a><a name="section-2.8"></a><p></p>
<h2>Advanced Hormone-Refractory Prostate Cancer</h2>
<p class="First"><a name="ID72"></a>A multicenter Phase 2 trial of MitoXANTRONE Injection and low-dose prednisone (M + P) was conducted in 27 symptomatic patients with hormone-refractory prostate cancer. Using NPCP (National Prostate Cancer Project) criteria for disease response, there was one partial responder and 12 patients with stable disease. However, nine patients or 33% achieved a palliative response defined on the basis of reduction in analgesic use or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity.</p>
<p>These findings led to the initiation of a randomized multicenter trial (CCI-MIT22) comparing the effectiveness of (M + P) to low-dose prednisone alone (P). Eligible patients were required to have metastatic or locally advanced disease that had progressed on standard hormonal therapy, a castrate serum testosterone level, and at least mild <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at study entry. MitoXANTRONE Injection was administered at a dose of 12 mg/m<span class="Sup">2 </span>by short IV infusion every 3 weeks. Prednisone was administered orally at a dose of 5 mg twice a day. Patients randomized to the prednisone arm were crossed over to the M + P arm if they progressed or if they were not improved after a minimum of 6 weeks of therapy with prednisone alone. </p>
<p>A total of 161 patients were randomized, 80 to the M + P arm and 81 to the P arm. The median MitoXANTRONE Injection dose administered was 12 mg/m<span class="Sup">2 </span>per cycle. The median cumulative MitoXANTRONE Injection dose administered was 73 mg/m<span class="Sup">2 </span>(range of 12 to 212 mg/m<span class="Sup">2</span>). </p>
<p>A primary palliative response (defined as a 2-point decrease in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity in a 6-point <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> scale, associated with stable analgesic use, and lasting a minimum of 6 weeks) was achieved in 29% of patients randomized to M + P compared to 12% of patients randomized to P alone (p = 0.011). Two responders left the study after meeting primary response criterion for two consecutive cycles. For the purposes of this analysis, these two patients were assigned a response duration of zero days. A secondary palliative response was defined as a 50% or greater decrease in analgesic use, associated with stable <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity, and lasting a minimum of 6 weeks. An overall palliative response (defined as primary plus secondary responses) was achieved in 38% of patients randomized to M + P compared to 21% of patients randomized to P (p = 0.025). The median duration of primary palliative response for patients randomized to M + P was 7.6 months compared to 2.1 months for patients randomized to P alone (p = 0.0009). The median duration of overall palliative response for patients randomized to M + P was 5.6 months compared to 1.9 months for patients randomized to P alone (p = 0.0004). </p>
<p>Time to progression was defined as a 1-point increase in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity, or a &gt; 25% increase in analgesic use, or evidence of disease progression on radiographic studies, or requirement for radiotherapy. The median time to progression for all patients randomized to M + P was 4.4 months compared to 2.3 months for all patients randomized to P alone (p = 0.0001). Median time to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was 11.3 months for all patients on the M + P arm compared to 10.8 months for all patients on P alone (p = 0.2324). </p>
<p>Forty-eight patients on the P arm crossed over to receive M + P. Of these, thirty patients had progressed on P, while 18 had stable disease on P. The median cycle of crossover was 5 cycles (range of 2 to 16 cycles). Time trends for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity prior to crossover were significantly worse for patients who crossed over than for those who remained on P alone (p = 0.012). Nine patients (19%) demonstrated a palliative response on M + P after crossover. The median time to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> for patients who crossed over to M + P was 12.7 months. </p>
<p>The clinical significance of a <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in prostate-specific antigen (PSA) concentrations after chemotherapy is unclear. On the CCI-MIT22 trial, a PSA <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> of 50% or greater for two consecutive follow-up assessments after baseline was reported in 33% of all patients randomized to the M + P arm and 9% of all patients randomized to the P arm. These findings should be interpreted with caution since PSA responses were not defined prospectively. A number of patients were inevaluable for response, and there was an imbalance between treatment arms in the numbers of evaluable patients. In addition, PSA reduction did not correlate precisely with palliative response, the primary efficacy endpoint of this study. For example, among the 26 evaluable patients randomized to the M + P arm who had a ≥ 50% reduction in PSA, only 13 had a primary palliative response. Also, among 42 evaluable patients on this arm who did not have this reduction in PSA, 8 nonetheless had a primary palliative response. </p>
<p>Investigators at Cancer and <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span> Group B (CALGB) conducted a Phase 3 comparative trial of MitoXANTRONE Injection plus hydrocortisone (M + H) versus hydrocortisone alone (H) in patients with hormone-refractory prostate cancer (CALGB 9182). Eligible patients were required to have <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span> that had progressed despite at least one hormonal therapy. Progression at study entry was defined on the basis of progressive symptoms, increases in measurable or osseous disease, or rising PSA levels. MitoXANTRONE Injection was administered intravenously at a dose of 14 mg/m<span class="Sup">2 </span>every 21 days and hydrocortisone was administered orally at a daily dose of 40 mg. A total of 242 subjects were randomized, 119 to the M + H arm and 123 to the H arm. There were no differences in survival between the two arms, with a median of 11.1 months in the M + H arm and 12 months in the H arm (p = 0.3298). Using NPCP criteria for response, partial responses were achieved in 10 patients (8.4%) randomized to the M + H arm compared with 2 patients (1.6%) randomized to the H arm (p = 0.018). The median time to progression, defined by NPCP criteria, for patients randomized to the M + H arm was 7.3 months compared to 4.1 months for patients randomized to H alone (p = 0.0654). </p>
<p>Approximately 60% of patients on each arm required analgesics at baseline. Analgesic use was measured in this study using a 5-point scale. The best percent change from baseline in mean analgesic use was -17% for 61 patients with available data on the M + H arm, compared with +17% for 61 patients on H alone (p = 0.014). A time trend analysis for analgesic use in individual patients also showed a trend favoring the M + H arm over H alone but was not statistically significant. </p>
<p><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> intensity was measured using the Symptom Distress Scale (SDS) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Item 2 (a 5 point scale). The best percent change from baseline in mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity was -14% for 37 patients with available data on the M + H arm, compared with +8% for 38 patients on H alone (p = 0.057). A time trend analysis for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity in individual patients showed no difference between treatment arms. </p>
</div>
<div class="Section">
<a name="ID73"></a><a name="section-2.9"></a><p></p>
<h2>Acute Nonlymphocytic <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span></h2>
<p class="First"><a name="ID74"></a>In two large randomized multicenter trials, remission induction therapy for acute nonlymphocytic <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> (ANLL) with MitoXANTRONE Injection 12 mg/m <span class="Sup">2 </span>daily for 3 days as a 10-minute intravenous infusion and cytarabine 100 mg/m<span class="Sup">2 </span>for 7 days given as a continuous 24-hour infusion was compared with daunorubicin 45 mg/m <span class="Sup">2 </span>daily by intravenous infusion for 3 days plus the same dose and schedule of cytarabine used with MitoXANTRONE Injection. Patients who had an incomplete antileukemic response received a second induction course in which MitoXANTRONE Injection or daunorubicin was administered for 2 days and cytarabine for 5 days using the same daily dosage schedule. Response rates and median survival information for both the U.S. and international multicenter trials are given in Table 3: </p>
<a name="ID164"></a><table width="100%">
<caption><span>Table 3 Response Rates, Time to Response, and Survival in U.S. and International Trials</span></caption>
<col width="31%">
<col width="13%">
<col width="13%">
<col width="11%">
<col width="10%">
<col width="11%">
<col width="11%">
<tfoot>
<tr class="First"><td align="left" colspan="7"><p class="First Footnote">MIT = MitoXANTRONE Injection + cytarabine <br></p></td></tr>
<tr class="Last"><td align="left" colspan="7"><p class="First Footnote">DAUN = daunorubicin + cytarabine<br></p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" colspan="1" valign="top"><span class="Bold"><br></span></td>
<td class="Toprule" align="center" colspan="2" valign="middle">
<span class="Bold">% </span><span class="Bold">Complete </span><span class="Bold"><br></span>
</td>
<td class="Toprule" align="center" colspan="2" valign="middle">
<span class="Bold">Median </span><span class="Bold">Time </span><span class="Bold"><br></span>
</td>
<td class="Toprule" align="center" colspan="2" valign="bottom">
<span class="Bold">Survival </span><span class="Bold">(</span><span class="Bold">days</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule" align="left" colspan="1" valign="top">
<span class="Bold">Trial</span><br>
</td>
<td class="Botrule" align="center" colspan="2" valign="middle">
<span class="Bold">Response </span><span class="Bold">(</span><span class="Bold">CR</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" colspan="2" valign="middle">
<span class="Bold">to </span><span class="Bold">CR </span><span class="Bold">(</span><span class="Bold">days</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" colspan="2" valign="bottom"><span class="Bold"><br></span></td>
</tr>
<tr>
<td class="Botrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Toprule" align="center" valign="top">
<span class="Underline">MIT</span><br>
</td>
<td class="Botrule Toprule" align="center" valign="top">
<span class="Underline">DAUN</span><br>
</td>
<td class="Botrule Toprule" align="center" valign="top">
<span class="Underline">MIT</span><br>
</td>
<td class="Botrule Toprule" align="center" valign="top">
<span class="Underline">DAUN</span><br>
</td>
<td class="Botrule Toprule" align="center" valign="top">
<span class="Underline">MIT</span><br>
</td>
<td class="Botrule Toprule" align="center" valign="top">
<span class="Underline">DAUN</span><br>
</td>
</tr>
<tr>
<td class="Botrule Toprule" align="left" valign="top">U. S.<br>
</td>
<td class="Botrule Toprule" align="center" valign="top">63 (62/98)<span class="Underline"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="top">53(54/102)<span class="Underline"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="top">35<span class="Underline"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="top">42<span class="Underline"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="top">312<span class="Underline"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="top">237<span class="Underline"><br></span>
</td>
</tr>
<tr class="Last">
<td class="Botrule Toprule" align="left" valign="top">International<br>
</td>
<td class="Botrule Toprule" align="center" valign="top">50 (56/112)<br>
</td>
<td class="Botrule Toprule" align="center" valign="top">51(62/123)<br>
</td>
<td class="Botrule Toprule" align="center" valign="top">36<br>
</td>
<td class="Botrule Toprule" align="center" valign="top">42<br>
</td>
<td class="Botrule Toprule" align="center" valign="top">192<br>
</td>
<td class="Botrule Toprule" align="center" valign="top">230<br>
</td>
</tr>
</tbody>
</table>
<p><a name="ID165"></a>In these studies, two consolidation courses were administered to complete responders on each arm. Consolidation therapy consisted of the same drug and daily dosage used for remission induction, but only 5 days of cytarabine and 2 days of MitoXANTRONE Injection or daunorubicin were given. The first consolidation course was administered 6 weeks after the start of the final induction course if the patient achieved a complete remission. The second consolidation course was generally administered 4 weeks later. Full hematologic recovery was necessary for patients to receive consolidation therapy. For the U.S. trial, median granulocyte nadirs for patients receiving MitoXANTRONE Injection + cytarabine for consolidation courses 1 and 2 were 10/mm<span class="Sup">3 </span>for both courses, and for those patients receiving daunorubicin + cytarabine nadirs were 170/mm<span class="Sup">3 </span>and 260/mm<span class="Sup">3</span>, respectively. Median platelet nadirs for patients who received MitoXANTRONE Injection + cytarabine for consolidation courses 1 and 2 were 17,000/mm<span class="Sup">3 </span>and 14,000/mm<span class="Sup">3</span>, respectively, and were 33,000/mm<span class="Sup">3 </span>and 22,000/mm<span class="Sup">3 </span>in courses 1 and 2 for those patients who received daunorubicin + cytarabine. The benefit of consolidation therapy in ANLL patients who achieve a complete remission remains controversial. However, in the only well-controlled prospective, randomized multicenter trials with MitoXANTRONE Injection in ANLL, consolidation therapy was given to all patients who achieved a complete remission. During consolidation in the U.S. study, two <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> occurred on the MitoXANTRONE Injection arm and one on the daunorubicin arm. However, in the international study there were eight <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> on the MitoXANTRONE Injection arm during consolidation which were related to the <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> and none on the daunorubicin arm where less <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> occurred. </p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID75"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><a name="ID76"></a>MitoXANTRONE Injection is indicated for reducing neurologic <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> (i.e., patients whose neurologic status is significantly abnormal between relapses). MitoXANTRONE Injection is not indicated in the treatment of patients with primary progressive <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>. </p>
<p>The clinical patterns of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>. </p>
<p>MitoXANTRONE Injection in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> related to advanced hormone-refractory prostate cancer. </p>
<p>MitoXANTRONE Injection in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid <span class="product-label-link" type="condition" conceptid="138708" conceptname="Acute leukemia">acute leukemias</span>. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID77"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><a name="ID78"></a>MitoXANTRONE Injection is contraindicated in patients who have demonstrated prior <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to it. </p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="ID79"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><a name="ID80"></a>WHEN MitoXANTRONE Injection IS USED IN HIGH DOSES (&gt; 14 mg/m<span class="Sup">2</span>/d x 3 days) SUCH AS INDICATED FOR THE TREATMENT OF <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">LEUKEMIA</span>, SEVERE <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">MYELOSUPPRESSION</span> WILL OCCUR. THEREFORE, IT IS RECOMMENDED THAT MitoXANTRONE Injection BE ADMINISTERED ONLY BY PHYSICIANS EXPERIENCED IN THE CHEMOTHERAPY OF THIS DISEASE. LABORATORY AND SUPPORTIVE SERVICES MUST BE AVAILABLE FOR HEMATOLOGIC AND CHEMISTRY MONITORING AND ADJUNCTIVE THERAPIES, INCLUDING ANTIBIOTICS. </p>
<p>BLOOD AND BLOOD PRODUCTS MUST BE AVAILABLE TO SUPPORT PATIENTS DURING THE EXPECTED PERIOD OF MEDULLARY HYPOPLASIA AND SEVERE <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">MYELOSUPPRESSION</span>. PARTICULAR CARE SHOULD BE GIVEN TO ASSURING FULL HEMATOLOGIC RECOVERY BEFORE UNDERTAKING CONSOLIDATION THERAPY (IF THIS TREATMENT IS USED) AND PATIENTS SHOULD BE MONITORED CLOSELY DURING THIS PHASE. MitoXANTRONE INJECTION ADMINISTERED AT ANY DOSE CAN CAUSE <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">MYELOSUPPRESSION</span>. </p>
<p>CONTAINS SODIUM METABISULPHITE, A SULPHITE THAT MAY CAUSE ALLERGIC-TYPE REACTIONS INCLUDING ANAPHYLACTIC SYMPTOMS AND LIFE-THREATENING OR LESS SEVERE <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">ASTHMATIC</span> EPISODES IN CERTAIN SUSCEPTIBLE PEOPLE. THE OVERALL PREVALENCE OF SULFITE SENSITIVITY IN THE GENERAL POPULATION IS UNKNOWN AND PROBABLY LOW. SULFITE SENSITIVITY IS SEEN MORE FREQUENTLY IN <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">ASTHMATIC</span> THAN IN NONASTHMATIC PEOPLE.</p>
<div class="Section">
<a name="ID81"></a><a name="section-5.1"></a><p></p>
<h2>General</h2>
<p class="First"><a name="ID82"></a>Patients with preexisting <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> as the result of prior drug therapy should not receive MitoXANTRONE Injection unless it is felt that the possible benefit from such treatment warrants the risk of further medullary suppression. </p>
<p>The safety of MitoXANTRONE Injection in patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> is not established (see <span class="Bold"><a href="#ID45">CLINICAL PHARMACOLOGY</a></span>). </p>
<p>Safety for use by routes other than intravenous administration has not been established. </p>
<p>MitoXANTRONE Injection is not indicated for subcutaneous, intramuscular, or intra-arterial injection. There have been reports of local/regional <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, some irreversible, following intra-arterial injection. </p>
<p>MitoXANTRONE Injection must not be given by intrathecal injection. There have been reports of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> and <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>, both central and peripheral, following intrathecal injection. These reports have included <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> leading to <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and severe neurologic sequelae, and <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> with bowel and bladder dysfunction. </p>
<p>Topoisomerase II inhibitors, including MitoXANTRONE Injection, have been associated with the development of secondary <span class="product-label-link" type="condition" conceptid="140352" conceptname="Acute myeloid leukemia, disease">acute myeloid leukemia</span> and <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>. </p>
</div>
<div class="Section">
<a name="ID83"></a><a name="section-5.2"></a><p></p>
<h2>Cardiac Effects</h2>
<p class="First"><a name="ID84"></a>Because of the possible danger of cardiac effects in patients previously treated with daunorubicin or doxorubicin, the benefit to risk ratio of MitoXANTRONE Injection therapy in such patients should be determined before starting therapy. Functional cardiac changes including decreases in left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> (LVEF) and irreversible <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> can occur with MitoXANTRONE Injection. Cardiac toxicity may be more common in patients with prior treatment with anthracyclines, prior mediastinal radiotherapy, or with preexisting cardiovascular disease. Such patients should have regular cardiac monitoring of LVEF from the initiation of therapy. Cancer patients who received cumulative doses of 140 mg/m<span class="Sup">2 </span>either alone or in combination with other chemotherapeutic agents had a cumulative 2.6% probability of clinical <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. In comparative oncology trials, the overall cumulative probability rate of moderate or severe decreases in LVEF at this dose was 13%. </p>
<div class="Section">
<a name="ID85"></a><a name="section-5.2.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">Multiple Sclerosis</span></h3>
<p class="First"><a name="ID86"></a>Changes in cardiac function may occur in patients with <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> treated with MitoXANTRONE Injection. In one controlled trial (Study 1, see <span class="Bold"><a href="#ID69">CLINICAL TRIALS, <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">Multiple Sclerosis</span></a></span>), two patients (2%) of 127 receiving MitoXANTRONE Injection, one receiving a 5 mg/m<span class="Sup">2 </span>dose and the other receiving the 12 mg/m<span class="Sup">2 </span>dose, had LVEF values that decreased to below 50%. An additional patient receiving 12 mg/m<span class="Sup">2</span>, who did not have LVEF measured, had a decrease in another echocardiographic measurement of ventricular function (fractional shortening) that led to discontinuation from the trial (see <span class="Bold"><a href="#ID118">ADVERSE REACTIONS, <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">Multiple Sclerosis</span></a></span>). There were no reports of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> in either controlled trial. </p>
<p>MS patients should be assessed for cardiac signs and symptoms by history, physical examination, ECG, and quantitative LVEF evaluation using appropriate methodology (ex. Echocardiogram, MUGA, MRI, etc.) prior to the start of MitoXANTRONE Injection therapy. MS patients with a baseline LVEF below the lower limit of normal should not be treated with MitoXANTRONE Injection. Subsequent LVEF and ECG evaluations are recommended if signs or symptoms of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> develop and prior to every dose administered to MS patients. MitoXANTRONE Injection should not be administered to MS patients who experience a reduction in LVEF to below the lower limit of normal, to those who experience a clinically significant reduction in LVEF, or to those who have received a cumulative lifetime dose of 140 mg/m<span class="Sup">2</span>. MS patients should have yearly quantitative LVEF evaluation after stopping MitoXANTRONE Injection to monitor for late-occurring cardiotoxicity. </p>
</div>
<div class="Section">
<a name="ID87"></a><a name="section-5.2.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span></h3>
<p class="First"><a name="ID88"></a>Acute <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> may occasionally occur in patients treated with MitoXANTRONE Injection for ANLL. In first-line comparative trials of MitoXANTRONE Injection + cytarabine vs daunorubicin + cytarabine in adult patients with previously untreated ANLL, therapy was associated with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> in 6.5% of patients on each arm. A causal relationship between drug therapy and cardiac effects is difficult to establish in this setting since myocardial function is frequently depressed by the <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> that often accompany the underlying disease. </p>
</div>
<div class="Section">
<a name="ID89"></a><a name="section-5.2.3"></a><p></p>
<h3>Hormone-Refractory Prostate Cancer</h3>
<p class="First"><a name="ID90"></a>Functional cardiac changes such as decreases in LVEF and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> may occur in patients with hormone-refractory prostate cancer treated with MitoXANTRONE Injection. In a randomized comparative trial of MitoXANTRONE Injection plus low-dose prednisone vs low-dose prednisone, 7 of 128 patients (5.5 %) treated with MitoXANTRONE Injection had a cardiac event defined as any decrease in LVEF below the normal range, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (n = 3), or <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>. Two patients had a prior history of cardiac disease. The total MitoXANTRONE Injection dose administered to patients with cardiac effects ranged from &gt; 48 to 212 mg/m<span class="Sup">2</span>. </p>
<p>Among 112 patients evaluable for safety on the MitoXANTRONE Injection + hydrocortisone arm of the CALGB trial, 18 patients (19%) had a reduction in cardiac function, 5 patients (5%) had <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">cardiac ischemia</span>, and 2 patients (2%) experienced <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>. The range of total MitoXANTRONE Injection doses administered to these patients is not available. </p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="ID91"></a><a name="section-5.3"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><a name="ID92"></a>MitoXANTRONE Injection may cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised to avoid becoming pregnant. Mitoxantrone is considered a potential human teratogen because of its mechanism of action and the developmental effects demonstrated by related agents. Treatment of pregnant rats during the organogenesis period of gestation was associated with <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">fetal growth retardation</span> at doses ≥ 0.1 mg/kg/day (0.01 times the recommended human dose on a mg/m<span class="Sup">2 </span>basis). When pregnant rabbits were treated during organogenesis, an increased incidence of <span class="product-label-link" type="condition" conceptid="4086393" conceptname="Premature delivery">premature delivery</span> was observed at doses ≥ 0.1 mg/kg/day (0.01 times the recommended human dose on a mg/m<span class="Sup">2 </span>basis). No teratogenic effects were observed in these studies, but the maximum doses tested were well below the recommended human dose (0.02 and 0.05 times in rats and rabbits, respectively, on a mg/m<span class="Sup">2 </span>basis). There are no adequate and well-controlled studies in pregnant women. Women with <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> who are biologically capable of becoming pregnant should have a pregnancy test prior to each dose, and the results should be known prior to administration of the drug. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risk to the fetus. </p>
</div>
<div class="Section">
<a name="ID93"></a><a name="section-5.4"></a><p></p>
<h2>Secondary <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span></h2>
<p class="First"><a name="ID94"></a>MitoXANTRONE Injection therapy increases the risk of developing secondary <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> in patients with cancer and in patients with <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>. </p>
<p>In a study of patients with prostate cancer, <span class="product-label-link" type="condition" conceptid="140352" conceptname="Acute myeloid leukemia, disease">acute myeloid leukemia</span> occurred in 1% (5/487) of mitoxantrone-treated patients versus no cases in the control group (0/496) not receiving mitoxantrone at 4.7 years followup. </p>
<p>In a prospective, open-label, tolerability and safety monitoring study of MitoXANTRONE Injection treated MS patients followed for up to five years (median of 2.8 years), <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> occurred in 0.6% (3/509) of patients. Publications describe <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> risks of 0.25% to 2.8% in cohorts of patients with MS treated with MitoXANTRONE Injection and followed for varying periods of time. This <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> risk exceeds the risk of <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> in the general population. The most commonly reported types were <span class="product-label-link" type="condition" conceptid="4103718" conceptname="Acute promyelocytic leukemia">acute promyelocytic leukemia</span> and <span class="product-label-link" type="condition" conceptid="140352" conceptname="Acute myeloid leukemia, disease">acute myelocytic leukemia</span>. </p>
<p>In 1774 patients with breast cancer who received MitoXANTRONE Injection concomitantly with other cytotoxic agents and radiotherapy, the cumulative risk of developing treatment-related <span class="product-label-link" type="condition" conceptid="140352" conceptname="Acute myeloid leukemia, disease">acute myeloid leukemia</span> was estimated as 1.1% and 1.6% at 5 and 10 years, respectively. The second largest report involved 449 patients with breast cancer treated with MitoXANTRONE Injection, usually in combination with radiotherapy and/or other cytotoxic agents. In this study, the cumulative probability of developing secondary <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> was estimated to be 2.2% at 4 years. </p>
<p>Secondary <span class="product-label-link" type="condition" conceptid="140352" conceptname="Acute myeloid leukemia, disease">acute myeloid leukemia</span> has also been reported in cancer patients treated with anthracyclines. MitoXANTRONE Injection is an anthracenedione, a related drug. The occurrence of secondary <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> is more common when anthracyclines are given in combination with DNA-damaging antineoplastic agents, when patients have been heavily pretreated with cytotoxic drugs, or when doses of anthracyclines have been escalated. Symptoms of <span class="product-label-link" type="condition" conceptid="138708" conceptname="Acute leukemia">acute leukemia</span> may include excessive <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and recurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ID95"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section">
<a name="ID96"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First"><a name="ID97"></a>Therapy with MitoXANTRONE Injection should be accompanied by close and frequent monitoring of hematologic and chemical laboratory parameters, as well as frequent patient observation. </p>
<p>Systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> should be treated concomitantly with or just prior to commencing therapy with MitoXANTRONE Injection. </p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID98"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First"><a name="ID99"></a><span class="Bold"><a href="#ID183">See FDA-approved patient labeling (Medication Guide)</a></span>. </p>
<p>Inform patients of the availability of a Medication Guide and instruct them to read the Medication Guide prior to initiating treatment with MitoXANTRONE Injection and prior to each infusion. Review the MitoXANTRONE Injection Medication Guide with every patient prior to initiation of treatment and periodically during treatment. Instruct patients that MitoXANTRONE Injection should be taken only as prescribed. </p>
<p>Advise patients that MitoXANTRONE Injection can cause <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> and inform patients of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>. Advise patients that MitoXANTRONE Injection can cause <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> that may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> even in people who have never had heart problems before, and inform patients of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. Advise patients receiving MitoXANTRONE Injection to treat <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> that they should receive cardiac monitoring prior to each MitoXANTRONE Injection dose and yearly after stopping MitoXANTRONE Injection. </p>
<p>MitoXANTRONE Injection may impart a blue to green color to the urine for 24 hours after administration, and patients should be advised to expect this during therapy. Bluish discoloration of the sclera may also occur.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="ID100"></a><a name="section-6.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First"><a name="ID101"></a>A complete blood count, including platelets, should be obtained prior to each course of MitoXANTRONE Injection and in the event that signs and symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> develop. Liver function tests should also be performed prior to each course of therapy. MitoXANTRONE Injection therapy in <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> patients with <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span> is not recommended because MitoXANTRONE Injection clearance is reduced by <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and no laboratory measurement can predict drug clearance and dose adjustments. </p>
<p>In <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> treatment, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> may occur as a result of rapid lysis of tumor cells by MitoXANTRONE Injection. Serum uric acid levels should be monitored and hypouricemic therapy instituted prior to the initiation of antileukemic therapy. </p>
<p>Women with <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> who are biologically capable of becoming pregnant, even if they are using birth control, should have a pregnancy test, and the results should be known, before receiving each dose of MitoXANTRONE Injection (see <span class="Bold"><a href="#ID91">WARNINGS, Pregnancy</a></span>). </p>
</div>
<div class="Section">
<a name="ID102"></a><a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><a name="ID103"></a>Carcinogenesis </p>
<p>Intravenous treatment of rats and mice, once every 21 days for 24 months, with MitoXANTRONE Injection resulted in an increased incidence of <span class="product-label-link" type="condition" conceptid="4012174" conceptname="Fibroma">fibroma</span> and external auditory canal tumors in rats at a dose of 0.03 mg/kg (0.02 fold the recommended human dose, on a mg/m<span class="Sup">2 </span>basis), and <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenoma</span> in male mice at a dose of 0.1 mg/kg (0.03 fold the recommended human dose, on a mg/m<span class="Sup">2 </span>basis). Intravenous treatment of rats, once every 21 days for 12 months with MitoXANTRONE Injection resulted in an increased incidence of external auditory canal tumors in rats at a dose of 0.3 mg/kg (0.15 fold the recommended human dose, on a mg/m<span class="Sup">2 </span>basis). </p>
<p>Mutagenesis </p>
<p>MitoXANTRONE Injection was clastogenic in the <span class="Italics">in vivo</span> rat bone marrow assay. MitoXANTRONE Injection was also clastogenic in two <span class="Italics">in vitro</span> assays; it induced DNA damage in primary rat hepatocytes and sister chromatid exchanges in Chinese hamster ovary cells. MitoXANTRONE Injection was mutagenic in bacterial and mammalian test systems (Ames/<span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> and E. coli and L5178Y TK+/-mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>). </p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID104"></a><a name="section-6.5"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First"><a name="ID105"></a>Mitoxantrone and its metabolites are excreted in bile and urine, but it is not known whether the metabolic or excretory pathways are saturable, may be inhibited or induced, or if mitoxantrone and its metabolites undergo enterohepatic circulation. To date, post-marketing experience has not revealed any significant drug interactions in patients who have received MitoXANTRONE Injection for treatment of cancer. Information on drug interactions in patients with <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> is limited. </p>
<p>Following concurrent administration of MitoXANTRONE Injection with corticosteroids, no evidence of drug interactions has been observed.</p>
</div>
<div class="Section">
<a name="ID106"></a><a name="section-6.6"></a><p></p>
<h2>Special Populations</h2>
<p class="First"><a name="ID107"></a><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> who have <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should ordinarily not be treated with MitoXANTRONE Injection. MitoXANTRONE Injection should be administered with caution to other patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. In patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, the AUC is more than three times greater than the value observed in patients with normal hepatic function. </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="ID108"></a><a name="section-6.7"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><a name="ID109"></a>Pregnancy Category D (see <span class="Bold"><a href="#ID91">WARNINGS</a></span>). </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID110"></a><a name="section-6.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First"><a name="ID111"></a>MitoXANTRONE Injection is excreted in human milk and significant concentrations (18 ng/mL) have been reported for 28 days after the last administration. Because of the potential for serious adverse reactions in infants from MitoXANTRONE Injection, breast feeding should be discontinued before starting treatment. </p>
</div>
<div class="Section">
<a name="ID112"></a><a name="section-6.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First"><a name="ID166"></a>Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID113"></a><a name="section-6.10"></a><p></p>
<h2>Geriatric Use:</h2>
<div class="Section">
<a name="ID114"></a><a name="section-6.10.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">Multiple Sclerosis</span></h3>
<p class="First"><a name="ID167"></a>Clinical studies of MitoXANTRONE Injection did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.</p>
</div>
<div class="Section">
<a name="ID115"></a><a name="section-6.10.2"></a><p></p>
<h3>Hormone-Refractory Prostate Cancer</h3>
<p class="First"><a name="ID168"></a>One hundred forty-six patients aged 65 and over and 52 younger patients (&lt;65 years) have been treated with MitoXANTRONE Injection in controlled clinical studies. These studies did not include sufficient numbers of younger patients to determine whether they respond differently from older patients. However, greater sensitivity of some older individuals cannot be ruled out.</p>
</div>
<div class="Section">
<a name="ID116"></a><a name="section-6.10.3"></a><p></p>
<h3>Acute Nonlymphocytic <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span></h3>
<p class="First"><a name="ID169"></a>Although definitive studies with MitoXANTRONE Injection have not been performed in geriatric patients with ANLL, toxicity may be more frequent in the elderly. Elderly patients are more likely to have age-related comorbidities due to disease or disease therapy.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID117"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section">
<a name="ID118"></a><a name="section-7.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">Multiple Sclerosis</span></h2>
<p class="First"><a name="ID119"></a>MitoXANTRONE Injection has been administered to 149 patients with <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> in two randomized clinical trials, including 21 patients who received MitoXANTRONE Injection in combination with corticosteroids. </p>
<p>In Study 1, the proportion of patients who discontinued treatment due to an adverse event was 9.7% (n = 6) in the 12 mg/m<span class="Sup">2 </span>MitoXANTRONE Injection arm (<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, decreased LV function, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and one discontinuation to prevent future complications from repeated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>) compared to 3.1% (n = 2) in the placebo arm (<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>). The following clinical adverse experiences were significantly more frequent in the MitoXANTRONE Injection groups: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, and <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">menstrual disorders</span>, including <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>. </p>
<p>Table 4a summarizes clinical adverse events of all intensities occurring in ≥ 5% of patients in either dose group of MitoXANTRONE Injection and that were numerically greater on drug than on placebo in Study 1. The majority of these events were of mild to moderate intensity, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> was the only adverse event that occurred with severe intensity in more than one patient (three patients [5%] in the 12 mg/m<span class="Sup">2 </span>group). Of note, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> consisted of mild <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair thinning</span>. </p>
<p>Two of the 127 patients treated with MitoXANTRONE Injection in Study 1 had decreased LVEF to below 50% at some point during the 2 years of treatment. An additional patient receiving 12 mg/m<span class="Sup">2 </span>did not have LVEF measured, but had another echocardiographic measure of ventricular function (fractional shortening) that led to discontinuation from the study. </p>
<a name="ID170"></a><table width="100%">
<caption><span>Table 4aAdverse Events of Any Intensity Occurring in ≥ 5% of Patients on Any Dose of MitoXANTRONE Injection and That Were Numerically Greater Than in the Placebo Group Study 1</span></caption>
<col width="39%">
<col width="18%">
<col width="21%">
<col width="22%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Percentage of female patients.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="middle"><br></td>
<td class="Botrule Toprule" align="center" valign="top">
<span class="Bold">Percent </span><span class="Bold">of </span><span class="Bold">Patients</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="top">
<span class="Bold">Percent </span><span class="Bold">of </span><span class="Bold">Patients</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="top">
<span class="Bold">Percent </span><span class="Bold">of </span><span class="Bold">Patients</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold"><br></span></td>
<td class="Toprule" align="center" valign="middle"><span class="Bold"><br></span></td>
<td class="Toprule" align="center" valign="middle">
<span class="Bold">5 </span><span class="Bold">mg</span><span class="Bold">/</span><span class="Bold">m<span class="Sup">2</span> </span><span class="Bold"><br></span>
</td>
<td class="Toprule" align="center" valign="middle">
<span class="Bold">12 </span><span class="Bold">mg</span><span class="Bold">/</span><span class="Bold">m<span class="Sup">2</span></span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold"><br></span></td>
<td align="center" valign="bottom"><span class="Bold"><br></span></td>
<td align="center" valign="middle">
<span class="Bold">MitoXANTRONE </span><span class="Bold"><br></span>
</td>
<td align="center" valign="middle">
<span class="Bold">MitoXANTRONE</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold"><br></span></td>
<td align="center" valign="bottom">
<span class="Bold">Placebo</span><span class="Bold"><br></span>
</td>
<td align="center" valign="middle">
<span class="Bold">Injection</span><span class="Bold"><br></span>
</td>
<td align="center" valign="middle">
<span class="Bold"> </span><span class="Bold">Injection</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="bottom">
<span class="Bold">Preferred </span><span class="Bold">Term</span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" valign="bottom">
<span class="Bold">(</span><span class="Bold">N </span><span class="Bold">= </span><span class="Bold">64</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">(</span><span class="Bold">N </span><span class="Bold">= </span><span class="Bold">65</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">(</span><span class="Bold">N </span><span class="Bold">= </span><span class="Bold">62</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Toprule" align="left" valign="middle">Nausea <br>
</td>
<td class="Toprule" align="center" valign="middle">20<br>
</td>
<td class="Toprule" align="center" valign="middle">55<br>
</td>
<td class="Toprule" align="center" valign="middle">76<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Alopecia <br>
</td>
<td align="center" valign="middle">31<br>
</td>
<td align="center" valign="middle">38<br>
</td>
<td align="center" valign="middle">61<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Menstrual disorder <a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a><span class="Sup"> </span><br>
</td>
<td align="center" valign="top">26<br>
</td>
<td align="center" valign="top">51<br>
</td>
<td align="center" valign="top">61<br>
</td>
</tr>
<tr>
<td align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span><span class="Sup"> </span><a href="#footnote-1" class="Sup">*</a> <br>
</td>
<td align="center" valign="middle">3<br>
</td>
<td align="center" valign="middle">28<br>
</td>
<td align="center" valign="middle">43<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Upper respiratory tract infection <br>
</td>
<td align="center" valign="middle">52<br>
</td>
<td align="center" valign="middle">51<br>
</td>
<td align="center" valign="middle">53<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Urinary tract infection <br>
</td>
<td align="center" valign="top">13<br>
</td>
<td align="center" valign="top">29<br>
</td>
<td align="center" valign="top">32<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Stomatitis <br>
</td>
<td align="center" valign="top">8<br>
</td>
<td align="center" valign="top">15<br>
</td>
<td align="center" valign="top">19<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Arrhythmia <br>
</td>
<td align="center" valign="middle">8<br>
</td>
<td align="center" valign="middle">6<br>
</td>
<td align="center" valign="middle">18<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Diarrhea <br>
</td>
<td align="center" valign="top">11<br>
</td>
<td align="center" valign="top">25<br>
</td>
<td align="center" valign="top">16<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Urine abnormal <br>
</td>
<td align="center" valign="middle">6<br>
</td>
<td align="center" valign="middle">5<br>
</td>
<td align="center" valign="middle">11<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">ECG abnormal <br>
</td>
<td align="center" valign="middle">3<br>
</td>
<td align="center" valign="middle">5<br>
</td>
<td align="center" valign="middle">11<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Constipation <br>
</td>
<td align="center" valign="middle">6<br>
</td>
<td align="center" valign="middle">14<br>
</td>
<td align="center" valign="middle">10<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Back pain <br>
</td>
<td align="center" valign="top">5<br>
</td>
<td align="center" valign="top">6<br>
</td>
<td align="center" valign="top">8<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Sinusitis <br>
</td>
<td align="center" valign="top">2<br>
</td>
<td align="center" valign="top">3<br>
</td>
<td align="center" valign="top">6<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="bottom">Headache <br>
</td>
<td class="Botrule" align="center" valign="bottom">5<br>
</td>
<td class="Botrule" align="center" valign="bottom">6<br>
</td>
<td class="Botrule" align="center" valign="bottom">6<br>
</td>
</tr>
</tbody>
</table>
<p><a name="ID171"></a>The proportion of patients experiencing any <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> during Study 1 was 67% for the placebo group, 85% for the 5 mg/m<span class="Sup">2 </span>group, and 81% for the 12 mg/m<span class="Sup">2 </span>group. However, few of these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> required hospitalization: one placebo patient (<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span>), three 5 mg/m<span class="Sup">2 </span>patients (<span class="product-label-link" type="condition" conceptid="201773" conceptname="Enteritis of small intestine">enteritis</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>), and four 12 mg/m<span class="Sup">2 </span>patients (<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> [two], <span class="product-label-link" type="condition" conceptid="4302765" conceptname="Endometritis">endometritis</span>). </p>
<p>Table 4b summarizes laboratory abnormalities that occurred in ≥ 5% of patients in either MitoXANTRONE Injection dose group, and that were numerically more frequent than in the placebo group. </p>
<a name="ID172"></a><table width="100%">
<caption><span>Table 4bLaboratory Abnormalities Occurring in ≥ 5% of Patients* on Either Dose of MitoXANTRONE Injection and That Were More Frequent Than in the Placebo Group Study 1</span></caption>
<col width="31%">
<col width="18%">
<col width="25%">
<col width="26%">
<tfoot>
<tr class="First"><td align="left" colspan="4"><p class="First Footnote"><span class="Sup">*</span> Assessed using World Health Organization (WHO) toxicity criteria. <br></p></td></tr>
<tr><td align="left" colspan="4"><p class="First Footnote">a. &lt; 4000 cells/mm<span class="Sup">3</span><span class="Sup"></span><br></p></td></tr>
<tr class="Last"><td align="left" colspan="4"><p class="First Footnote">b. &lt; 2000 cells/mm<span class="Sup">3</span><span class="Sup"></span><br></p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="top"><span class="Bold"><br></span></td>
<td class="Botrule Toprule" align="center" valign="middle">
<span class="Bold">Percent </span><span class="Bold">of </span><span class="Bold">Patients</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="middle">
<span class="Bold">Percent </span><span class="Bold">of </span><span class="Bold">Patients</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="middle">
<span class="Bold">Percent </span><span class="Bold">of </span><span class="Bold">Patients</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td align="center" valign="middle"><span class="Bold"><br></span></td>
<td class="Toprule" align="left" valign="middle"><span class="Bold"><br></span></td>
<td class="Toprule" align="center" valign="middle">
<span class="Bold">5 </span><span class="Bold">mg</span><span class="Bold">/</span><span class="Bold">m<span class="Sup">2</span></span><span class="Bold"><br></span>
</td>
<td class="Toprule" align="center" valign="middle">
<span class="Bold">12 </span><span class="Bold">mg</span><span class="Bold">/</span><span class="Bold">m<span class="Sup">2</span><span class="Sup"> </span></span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold"><br></span></td>
<td align="left" valign="bottom"><span class="Bold"><br></span></td>
<td align="center" valign="middle">
<span class="Bold">MitoXANTRONE</span><span class="Bold"><br></span>
</td>
<td align="center" valign="middle">
<span class="Bold">MitoXANTRONE</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold"><br></span></td>
<td align="center" valign="bottom">
<span class="Bold">Placebo</span><span class="Bold"><br></span>
</td>
<td align="center" valign="middle">
<span class="Bold"> </span><span class="Bold">Injection</span><span class="Bold"><br></span>
</td>
<td align="center" valign="middle">
<span class="Bold"> </span><span class="Bold">Injection  </span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="bottom">
<span class="Bold">Event</span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" valign="bottom">
<span class="Bold">(</span><span class="Bold">N </span><span class="Bold">= </span><span class="Bold">64</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">(</span><span class="Bold">N </span><span class="Bold">= </span><span class="Bold">65</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">(</span><span class="Bold">N </span><span class="Bold">= </span><span class="Bold">62</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Toprule" align="left" valign="top">Leukopenia <span class="Sup">a</span><span class="Sup"> </span><br>
</td>
<td class="Toprule" align="center" valign="middle">0<br>
</td>
<td class="Toprule" align="center" valign="middle">9<br>
</td>
<td class="Toprule" align="center" valign="middle">19<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Gamma-GT increased <br>
</td>
<td align="center" valign="middle">3<br>
</td>
<td align="center" valign="middle">3<br>
</td>
<td align="center" valign="middle">15<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">SGOT increased <br>
</td>
<td align="center" valign="middle">8<br>
</td>
<td align="center" valign="middle">9<br>
</td>
<td align="center" valign="middle">8<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Granulocytopenia <span class="Sup">b</span><span class="Sup"> </span><br>
</td>
<td align="center" valign="middle">2<br>
</td>
<td align="center" valign="middle">6<br>
</td>
<td align="center" valign="middle">6<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Anemia <br>
</td>
<td align="center" valign="middle">2<br>
</td>
<td align="center" valign="middle">9<br>
</td>
<td align="center" valign="middle">6<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="bottom">SGPT increased <br>
</td>
<td class="Botrule" align="center" valign="middle">3<br>
</td>
<td class="Botrule" align="center" valign="middle">6<br>
</td>
<td class="Botrule" align="center" valign="middle">5<br>
</td>
</tr>
</tbody>
</table>
<p><a name="ID173"></a>There was no difference among treatment groups in the incidence or severity of hemorrhagic events. </p>
<p>In Study 2, MitoXANTRONE Injection was administered once a month. Clinical adverse events most frequently reported in the MitoXANTRONE Injection group included <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> (53% of female patients), <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> (33% of patients), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (29% of patients), and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> (24% of patients). Tables 5a and 5b respectively summarize adverse events and laboratory abnormalities occurring in &gt; 5% of patients in the MitoXANTRONE Injection group and numerically more frequent than in the control group. </p>
<a name="ID174"></a><table width="100%">
<caption><span>Table 5a Adverse Events of Any Intensity Occurring in &gt; 5% of Patients<span class="Sup">*</span> in the MitoXANTRONE Injection Group and Numerically More Frequent Than in the Control Group Study 2</span></caption>
<col width="56%">
<col width="22%">
<col width="22%">
<tfoot>
<tr class="First"><td align="left" colspan="3"><p class="First Footnote">M = MitoXANTRONE Injection, MP = methylprednisolone<br></p></td></tr>
<tr><td align="left" colspan="3"><p class="First Footnote"><span class="Sup">*</span> Assessed using National Cancer Institute (NCI) common toxicity criteria. <br></p></td></tr>
<tr class="Last"><td align="left" colspan="3"><p class="First Footnote">a. Percentage of female patients. <br></p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="bottom"><span class="Bold"><br></span></td>
<td class="Botrule Toprule" align="center" valign="middle">
<span class="Bold">Percent </span><span class="Bold">of </span><span class="Bold">Patients</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="middle">
<span class="Bold">Percent </span><span class="Bold">of </span><span class="Bold">Patients</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold"><br></span></td>
<td class="Toprule" align="center" valign="middle">
<span class="Bold">MP</span><span class="Bold"><br></span>
</td>
<td class="Toprule" align="center" valign="middle">
<span class="Bold">M </span><span class="Bold">+ </span><span class="Bold">MP</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">
<span class="Bold">Event</span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">(</span><span class="Bold">n </span><span class="Bold">= </span><span class="Bold">21</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">(</span><span class="Bold">n </span><span class="Bold">= </span><span class="Bold">21</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Toprule" align="left" valign="top">Amenorrhea <span class="Sup">a</span> <br>
</td>
<td class="Toprule" align="center" valign="middle">0<br>
</td>
<td class="Toprule" align="center" valign="middle">53<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Alopecia <br>
</td>
<td align="center" valign="middle">0<br>
</td>
<td align="center" valign="middle">33<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Nausea <br>
</td>
<td align="center" valign="middle">0<br>
</td>
<td align="center" valign="middle">29<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Asthenia <br>
</td>
<td align="center" valign="middle">0<br>
</td>
<td align="center" valign="middle">24<br>
</td>
</tr>
<tr>
<td align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>/throat infection <br>
</td>
<td align="center" valign="middle">5<br>
</td>
<td align="center" valign="middle">19<br>
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Gastralgia</span>/stomach burn/epigastric pain <br>
</td>
<td align="center" valign="middle">5<br>
</td>
<td align="center" valign="middle">14<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Aphthosis <br>
</td>
<td align="center" valign="middle">0<br>
</td>
<td align="center" valign="middle">10<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Cutaneous mycosis <br>
</td>
<td align="center" valign="middle">0<br>
</td>
<td align="center" valign="middle">10<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Rhinitis <br>
</td>
<td align="center" valign="middle">0<br>
</td>
<td align="center" valign="middle">10<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Menorrhagia <span class="Sup">a</span> <br>
</td>
<td class="Botrule" align="center" valign="middle">0<br>
</td>
<td class="Botrule" align="center" valign="middle">7<br>
</td>
</tr>
</tbody>
</table>
<a name="ID175"></a><table width="100%">
<caption><span>Table 5b  Laboratory Abnormalities Occurring in &gt; 5% of Patients* in the MitoXANTRONE Injection Group and Numerically More Frequent Than in the Control Group Study 2</span></caption>
<col width="60%">
<col width="23%">
<col width="17%">
<tfoot>
<tr class="First"><td align="left" colspan="3"><p class="First Footnote">M = MitoXANTRONE Injection, MP = methylprednisolone. <br></p></td></tr>
<tr><td align="left" colspan="3"><p class="First Footnote"><span class="Sup">*</span><span class="Sup"></span>Assessed using National Cancer Institute (NCI) common toxicity criteria. <br></p></td></tr>
<tr><td align="left" colspan="3"><p class="First Footnote">a. &lt; 4000 cells/mm<span class="Sup">3</span><span class="Sup"></span><br></p></td></tr>
<tr><td align="left" colspan="3"><p class="First Footnote">b. &lt; 1500 cells/mm<span class="Sup">3</span><span class="Sup"></span><br></p></td></tr>
<tr class="Last"><td align="left" colspan="3"><p class="First Footnote">c. &lt; 100,000 cells/mm<span class="Sup">3</span><span class="Sup"></span><br></p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="bottom"><span class="Bold"><br></span></td>
<td class="Botrule Toprule" align="center" valign="middle">
<span class="Bold">Percent </span><span class="Bold">of </span><span class="Bold">Patients</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="middle">
<span class="Bold">Percent </span><span class="Bold">of </span><span class="Bold">Patients</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold"><br></span></td>
<td class="Toprule" align="center" valign="middle">
<span class="Bold">MP</span><span class="Bold"><br></span>
</td>
<td class="Toprule" align="center" valign="middle">
<span class="Bold">M </span><span class="Bold">+ </span><span class="Bold">MP</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="bottom">
<span class="Bold">Event</span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">(</span><span class="Bold">n </span><span class="Bold">= </span><span class="Bold">21</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">(</span><span class="Bold">n </span><span class="Bold">= </span><span class="Bold">21</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Toprule" align="left" valign="top">WBC low <span class="Sup">a</span><span class="Sup"> </span><br>
</td>
<td class="Toprule" align="center" valign="middle">14<br>
</td>
<td class="Toprule" align="center" valign="middle">100<br>
</td>
</tr>
<tr>
<td align="left" valign="top">ANC low <span class="Sup">b</span> <br>
</td>
<td align="center" valign="middle">10<br>
</td>
<td align="center" valign="middle">100<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Lymphocytes low <br>
</td>
<td align="center" valign="middle">43<br>
</td>
<td align="center" valign="middle">95<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Hemoglobin low <br>
</td>
<td align="center" valign="middle">48<br>
</td>
<td align="center" valign="middle">43<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Platelets low <span class="Sup">c</span><span class="Sup"> </span><br>
</td>
<td align="center" valign="middle">0<br>
</td>
<td align="center" valign="middle">33<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">SGOT high <br>
</td>
<td align="center" valign="middle">5<br>
</td>
<td align="center" valign="middle">15<br>
</td>
</tr>
<tr>
<td align="left" valign="top">SGPT high <br>
</td>
<td align="center" valign="middle">10<br>
</td>
<td align="center" valign="middle">15<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Glucose high <br>
</td>
<td align="center" valign="middle">5<br>
</td>
<td align="center" valign="middle">10<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Potassium low <br>
</td>
<td class="Botrule" align="center" valign="middle">0<br>
</td>
<td class="Botrule" align="center" valign="middle">10<br>
</td>
</tr>
</tbody>
</table>
<p><a name="ID176"></a><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> were reported in the M +MP group (see Table 5b). </p>
<p><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> occurred within 3 weeks after MitoXANTRONE Injection administration and was always reversible. Only mild to moderate intensity <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were reported in 9 of 21 patients in the M +MP group and in 3 of 21 patients in the MP group; none of these required hospitalization. There was no difference among treatment groups in the incidence or severity of hemorrhagic events. There were no withdrawals from Study 2 for safety reasons. </p>
</div>
<div class="Section">
<a name="ID120"></a><a name="section-7.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span></h2>
<p class="First"><a name="ID121"></a>MitoXANTRONE Injection has been studied in approximately 600 patients with acute non-<span class="product-label-link" type="condition" conceptid="132853" conceptname="Lymphoid leukemia">lymphocytic leukemia</span> (ANLL). Table 6 represents the adverse reaction experience in the large U.S. comparative study of mitoxantrone + cytarabine vs daunorubicin + cytarabine. Experience in the large international study was similar. A much wider experience in a variety of other tumor types revealed no additional important reactions other than <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> (see <span class="Bold"><a href="#ID79">WARNINGS</a></span>). It should be appreciated that the listed adverse reaction categories include overlapping clinical symptoms related to the same condition, e.g., <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>. In addition, the listed adverse reactions cannot all necessarily be attributed to chemotherapy as it is often impossible to distinguish effects of the drug and effects of the underlying disease. It is clear, however, that the combination of MitoXANTRONE Injection + cytarabine was responsible for <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span>/<span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, and <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>. </p>
<p>Table 6 summarizes adverse reactions occurring in patients treated with MitoXANTRONE Injection + cytarabine in comparison with those who received daunorubicin + cytarabine for therapy of ANLL in a large multicenter randomized prospective U.S. trial. </p>
<p>Adverse reactions are presented as major categories and selected examples of clinically significant subcategories.</p>
<a name="ID177"></a><table width="101%">
<caption><span>Table 6 Adverse Events Occurring in ANLL Patients Receiving MitoXANTRONE Injection or Daunorubicin</span></caption>
<col width="31%">
<col width="17%">
<col width="17%">
<col width="18%">
<col width="18%">
<tfoot><tr class="First Last"><td align="left" colspan="5"><p class="First Footnote"><span class="Underline">MIT </span>= MitoXANTRONE Injection, DAUN = daunorubicin. <br></p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="top"><span class="Bold"><br></span></td>
<td class="Toprule" align="center" valign="middle">
<span class="Bold">Induction</span><span class="Bold"><br></span>
</td>
<td class="Toprule" align="center" valign="middle">
<span class="Bold">Induction</span><span class="Bold"><br></span>
</td>
<td class="Toprule" align="center" valign="middle">
<span class="Bold">Consolidation</span><span class="Bold"><br></span>
</td>
<td class="Toprule" align="center" valign="middle">
<span class="Bold">Consolidation</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold"><br></span></td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">[% </span><span class="Bold">pts </span><span class="Bold">entering </span><span class="Bold">induction</span><span class="Bold">] </span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">[% </span><span class="Bold">pts </span><span class="Bold">entering </span><span class="Bold">induction</span><span class="Bold">]</span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">[% </span><span class="Bold">pts </span><span class="Bold">entering </span><span class="Bold">induction</span><span class="Bold">] </span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">[% </span><span class="Bold">pts </span><span class="Bold">entering </span><span class="Bold">induction</span><span class="Bold">]</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold"><br></span></td>
<td class="Toprule" align="center" valign="middle">
<span class="Bold Underline">MIT</span><span class="Bold"><br></span>
</td>
<td class="Toprule" align="center" valign="middle">
<span class="Bold Underline">DAUN</span><span class="Bold"><br></span>
</td>
<td class="Toprule" align="center" valign="middle">
<span class="Bold Underline">MIT</span><span class="Bold"><br></span>
</td>
<td class="Toprule" align="center" valign="middle">
<span class="Bold Underline">DAUN</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="bottom">
<span class="Bold">Event</span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">N </span><span class="Bold">= </span><span class="Bold">102</span><span class="Bold Underline"><br></span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">N </span><span class="Bold">= </span><span class="Bold">102</span><span class="Bold Underline"><br></span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">N </span><span class="Bold">= </span><span class="Bold">55</span><span class="Bold Underline"><br></span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">N </span><span class="Bold">= </span><span class="Bold">49</span><span class="Bold Underline"><br></span>
</td>
</tr>
<tr>
<td class="Toprule" align="left" valign="top">Cardiovascular <br>
</td>
<td class="Toprule" align="center" valign="middle">26<br>
</td>
<td class="Toprule" align="center" valign="middle">28<br>
</td>
<td class="Toprule" align="center" valign="middle">11<br>
</td>
<td class="Toprule" align="center" valign="middle">24<br>
</td>
</tr>
<tr>
<td align="justify" valign="middle">CHF <br>
</td>
<td align="center" valign="middle">5<br>
</td>
<td align="center" valign="middle">6<br>
</td>
<td align="center" valign="middle">0<br>
</td>
<td align="center" valign="middle">0<br>
</td>
</tr>
<tr>
<td align="justify" valign="middle">Arrhythmias <br>
</td>
<td align="center" valign="middle">3<br>
</td>
<td align="center" valign="middle">3<br>
</td>
<td align="center" valign="middle">4<br>
</td>
<td align="center" valign="middle">4<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Bleeding <br>
</td>
<td align="center" valign="middle">37<br>
</td>
<td align="center" valign="middle">41<br>
</td>
<td align="center" valign="middle">20<br>
</td>
<td align="center" valign="middle">6<br>
</td>
</tr>
<tr>
<td align="left" valign="top">GI <br>
</td>
<td align="center" valign="middle">16<br>
</td>
<td align="center" valign="middle">12<br>
</td>
<td align="center" valign="middle">2<br>
</td>
<td align="center" valign="middle">2<br>
</td>
</tr>
<tr>
<td align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">Petechiae</span>/ecchymoses <br>
</td>
<td align="center" valign="middle">7<br>
</td>
<td align="center" valign="middle">9<br>
</td>
<td align="center" valign="middle">11<br>
</td>
<td align="center" valign="middle">2<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Gastrointestinal <br>
</td>
<td align="center" valign="middle">88<br>
</td>
<td align="center" valign="middle">85<br>
</td>
<td align="center" valign="middle">58<br>
</td>
<td align="center" valign="middle">51<br>
</td>
</tr>
<tr>
<td align="left" valign="middle"> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/vomiting <br>
</td>
<td align="center" valign="middle">72<br>
</td>
<td align="center" valign="middle">67<br>
</td>
<td align="center" valign="middle">31<br>
</td>
<td align="center" valign="middle">31<br>
</td>
</tr>
<tr>
<td align="left" valign="top"> Diarrhea <br>
</td>
<td align="center" valign="middle">47<br>
</td>
<td align="center" valign="middle">47<br>
</td>
<td align="center" valign="middle">18<br>
</td>
<td align="center" valign="middle">8<br>
</td>
</tr>
<tr>
<td align="left" valign="middle"> Abdominal pain <br>
</td>
<td align="center" valign="middle">15<br>
</td>
<td align="center" valign="middle">9<br>
</td>
<td align="center" valign="middle">9<br>
</td>
<td align="center" valign="middle">4<br>
</td>
</tr>
<tr>
<td align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">Mucositis</span>/stomatitis <br>
</td>
<td align="center" valign="middle">29<br>
</td>
<td align="center" valign="middle">33<br>
</td>
<td align="center" valign="middle">18<br>
</td>
<td align="center" valign="middle">8<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Hepatic <br>
</td>
<td align="center" valign="middle">10<br>
</td>
<td align="center" valign="middle">11<br>
</td>
<td align="center" valign="middle">14<br>
</td>
<td align="center" valign="middle">2<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Jaundice <br>
</td>
<td align="center" valign="middle">3<br>
</td>
<td align="center" valign="middle">8<br>
</td>
<td align="center" valign="middle">7<br>
</td>
<td align="center" valign="middle">0<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Infections <br>
</td>
<td align="center" valign="middle">66<br>
</td>
<td align="center" valign="middle">73<br>
</td>
<td align="center" valign="middle">60<br>
</td>
<td align="center" valign="middle">43<br>
</td>
</tr>
<tr>
<td align="left" valign="middle"> UTI <br>
</td>
<td align="center" valign="middle">7<br>
</td>
<td align="center" valign="middle">2<br>
</td>
<td align="center" valign="middle">7<br>
</td>
<td align="center" valign="middle">2<br>
</td>
</tr>
<tr>
<td align="left" valign="middle"> Pneumonia <br>
</td>
<td align="center" valign="middle">9<br>
</td>
<td align="center" valign="middle">7<br>
</td>
<td align="center" valign="middle">9<br>
</td>
<td align="center" valign="middle">0<br>
</td>
</tr>
<tr>
<td align="left" valign="middle"> Sepsis <br>
</td>
<td align="center" valign="middle">34<br>
</td>
<td align="center" valign="middle">36<br>
</td>
<td align="center" valign="middle">31<br>
</td>
<td align="center" valign="middle">18<br>
</td>
</tr>
<tr>
<td align="left" valign="top"> Fungal infections <br>
</td>
<td align="center" valign="middle">15<br>
</td>
<td align="center" valign="middle">13<br>
</td>
<td align="center" valign="middle">9<br>
</td>
<td align="center" valign="middle">6<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Renal failure <br>
</td>
<td align="center" valign="middle">8<br>
</td>
<td align="center" valign="middle">6<br>
</td>
<td align="center" valign="middle">0<br>
</td>
<td align="center" valign="middle">2<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Fever <br>
</td>
<td align="center" valign="middle">78<br>
</td>
<td align="center" valign="middle">71<br>
</td>
<td align="center" valign="middle">24<br>
</td>
<td align="center" valign="middle">18<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Alopecia <br>
</td>
<td align="center" valign="middle">37<br>
</td>
<td align="center" valign="middle">40<br>
</td>
<td align="center" valign="middle">22<br>
</td>
<td align="center" valign="middle">16<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Pulmonary <br>
</td>
<td align="center" valign="middle">43<br>
</td>
<td align="center" valign="middle">43<br>
</td>
<td align="center" valign="middle">24<br>
</td>
<td align="center" valign="middle">14<br>
</td>
</tr>
<tr>
<td align="left" valign="top">  Cough <br>
</td>
<td align="center" valign="middle">13<br>
</td>
<td align="center" valign="middle">9<br>
</td>
<td align="center" valign="middle">9<br>
</td>
<td align="center" valign="middle">2<br>
</td>
</tr>
<tr>
<td align="left" valign="top">  Dyspnea <br>
</td>
<td align="center" valign="middle">18<br>
</td>
<td align="center" valign="middle">20<br>
</td>
<td align="center" valign="middle">6<br>
</td>
<td align="center" valign="middle">0<br>
</td>
</tr>
<tr>
<td align="left" valign="top">CNS <br>
</td>
<td align="center" valign="middle">30<br>
</td>
<td align="center" valign="middle">30<br>
</td>
<td align="center" valign="middle">34<br>
</td>
<td align="center" valign="middle">35<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">  Seizures <br>
</td>
<td align="center" valign="middle">4<br>
</td>
<td align="center" valign="middle">4<br>
</td>
<td align="center" valign="middle">2<br>
</td>
<td align="center" valign="middle">8<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">  Headache <br>
</td>
<td align="center" valign="middle">10<br>
</td>
<td align="center" valign="middle">9<br>
</td>
<td align="center" valign="middle">13<br>
</td>
<td align="center" valign="middle">8<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Eye <br>
</td>
<td align="center" valign="middle">7<br>
</td>
<td align="center" valign="middle">6<br>
</td>
<td align="center" valign="middle">2<br>
</td>
<td align="center" valign="middle">4<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">  Conjunctivitis <br>
</td>
<td class="Botrule" align="center" valign="middle">5<br>
</td>
<td class="Botrule" align="center" valign="middle">1<br>
</td>
<td class="Botrule" align="center" valign="middle">0<br>
</td>
<td class="Botrule" align="center" valign="middle">0<br>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section">
<a name="ID122"></a><a name="section-7.3"></a><p></p>
<h2>Hormone-Refractory Prostate Cancer</h2>
<p class="First"><a name="ID123"></a>Detailed safety information is available for a total of 353 patients with hormone-refractory prostate cancer treated with MitoXANTRONE Injection, including 274 patients who received MitoXANTRONE Injection in combination with corticosteroids. </p>
<p>Table 7 summarizes adverse reactions of all grades occurring in ≥ 5% of patients in Trial CCI-MIT22. </p>
<a name="ID178"></a><table width="101%">
<caption><span>Table 7 Adverse Events of Any Intensity Occurring in ≥ 5% of Patients Trial CCI-MIT22</span></caption>
<col width="47%">
<col width="26%">
<col width="28%">
<tfoot><tr class="First Last"><td align="left" colspan="3"><p class="First Footnote">M = MitoXANTRONE Injection, P = prednisone.<br></p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="bottom"><span class="Bold"><br></span></td>
<td class="Toprule" align="center" valign="middle">
<span class="Bold">M </span><span class="Bold">+ </span><span class="Bold">P</span><span class="Bold"><br></span>
</td>
<td class="Toprule" align="center" valign="middle">
<span class="Bold">P</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold"><br></span></td>
<td align="center" valign="middle">
<span class="Bold">(</span><span class="Bold">n </span><span class="Bold">= </span><span class="Bold">80</span><span class="Bold">) </span><span class="Bold"><br></span>
</td>
<td align="center" valign="middle">
<span class="Bold">  </span><span class="Bold">(</span><span class="Bold">n </span><span class="Bold">= </span><span class="Bold">81</span><span class="Bold">) </span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="bottom">
<span class="Bold">Event</span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">%</span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">%</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Toprule" align="left" valign="middle">Nausea <br>
</td>
<td class="Toprule" align="center" valign="middle">61<br>
</td>
<td class="Toprule" align="center" valign="middle">35<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Fatigue <br>
</td>
<td align="center" valign="middle">39<br>
</td>
<td align="center" valign="middle">14<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Alopecia <br>
</td>
<td align="center" valign="middle">29<br>
</td>
<td align="center" valign="middle">0<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Anorexia <br>
</td>
<td align="center" valign="middle">25<br>
</td>
<td align="center" valign="middle">6<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Constipation <br>
</td>
<td align="center" valign="middle">16<br>
</td>
<td align="center" valign="middle">14<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Dyspnea <br>
</td>
<td align="center" valign="middle">11<br>
</td>
<td align="center" valign="middle">5<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Nail bed changes <br>
</td>
<td align="center" valign="middle">11<br>
</td>
<td align="center" valign="middle">0<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Edema <br>
</td>
<td align="center" valign="middle">10<br>
</td>
<td align="center" valign="middle">4<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Systemic infection <br>
</td>
<td align="center" valign="middle">10<br>
</td>
<td align="center" valign="middle">7<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Mucositis <br>
</td>
<td align="center" valign="middle">10<br>
</td>
<td align="center" valign="middle">0<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">UTI <br>
</td>
<td align="center" valign="middle">9<br>
</td>
<td align="center" valign="middle">4<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Emesis <br>
</td>
<td align="center" valign="middle">9<br>
</td>
<td align="center" valign="middle">5<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Pain <br>
</td>
<td align="center" valign="middle">8<br>
</td>
<td align="center" valign="middle">9<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Fever <br>
</td>
<td align="center" valign="middle">6<br>
</td>
<td align="center" valign="middle">3<br>
</td>
</tr>
<tr>
<td align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span>/bruise <br>
</td>
<td align="center" valign="middle">6<br>
</td>
<td align="center" valign="middle">1<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Anemia <br>
</td>
<td align="center" valign="middle">5<br>
</td>
<td align="center" valign="middle">3<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Cough <br>
</td>
<td align="center" valign="middle">5<br>
</td>
<td align="center" valign="middle">0<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Decreased LVEF <br>
</td>
<td align="center" valign="middle">5<br>
</td>
<td align="center" valign="middle">0<br>
</td>
</tr>
<tr>
<td align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>/depression <br>
</td>
<td align="center" valign="middle">5<br>
</td>
<td align="center" valign="middle">3<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Dyspepsia <br>
</td>
<td align="center" valign="middle">5<br>
</td>
<td align="center" valign="middle">6<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Skin infection <br>
</td>
<td align="center" valign="middle">5<br>
</td>
<td align="center" valign="middle">3<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="bottom">Blurred vision <br>
</td>
<td class="Botrule" align="center" valign="middle">3<br>
</td>
<td class="Botrule" align="center" valign="middle">5<br>
</td>
</tr>
</tbody>
</table>
<p><a name="ID179"></a>No nonhematologic adverse events of Grade 3/4 were seen in &gt; 5% of patients. </p>
<p>Table 8 summarizes adverse events of all grades occurring in ≥ 5% of patients in Trial CALGB 9182. </p>
<a name="ID180"></a><table width="100%">
<caption><span>Table 8 Adverse Events of Any Intensity Occurring in ≥ 5 % of Patients Trial CALGB 9182</span></caption>
<col width="37%">
<col width="17%">
<col width="17%">
<col width="16%">
<col width="13%">
<tfoot><tr class="First Last"><td align="left" colspan="5"><p class="First Footnote">M= MitoXANTRONE Injection, H= hydrocortisone <br></p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="bottom"><span class="Bold"><br></span></td>
<td class="Toprule" align="center" valign="middle">
<span class="Bold">M </span><span class="Bold">+ </span><span class="Bold">H</span><span class="Bold"><br></span>
</td>
<td class="Toprule" align="center" valign="middle">
<span class="Bold">M </span><span class="Bold">+ </span><span class="Bold">H</span><span class="Bold"><br></span>
</td>
<td class="Toprule" align="center" valign="middle">
<span class="Bold">H</span><span class="Bold"><br></span>
</td>
<td class="Toprule" align="center" valign="middle">
<span class="Bold">H</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold"><br></span></td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">(</span><span class="Bold">n </span><span class="Bold">= </span><span class="Bold">112</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">(</span><span class="Bold">n </span><span class="Bold">= </span><span class="Bold">112</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">(</span><span class="Bold">n </span><span class="Bold">= </span><span class="Bold">113</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">(</span><span class="Bold">n </span><span class="Bold">= </span><span class="Bold">113</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule" align="center" valign="top">
<span class="Bold">Event</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="middle">
<span class="Bold">n</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="middle">
<span class="Bold">%</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="middle">
<span class="Bold">n</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="middle">
<span class="Bold">%</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Toprule" align="left" valign="middle">Decreased WBC <br>
</td>
<td class="Toprule" align="center" valign="middle">96<br>
</td>
<td class="Toprule" align="center" valign="middle">87<br>
</td>
<td class="Toprule" align="center" valign="middle">4<br>
</td>
<td class="Toprule" align="center" valign="middle">4<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Abnormal granulocytes/bands <br>
</td>
<td align="center" valign="middle">88<br>
</td>
<td align="center" valign="middle">79<br>
</td>
<td align="center" valign="middle">3<br>
</td>
<td align="center" valign="middle">3<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Decreased hemoglobin <br>
</td>
<td align="center" valign="middle">83<br>
</td>
<td align="center" valign="middle">75<br>
</td>
<td align="center" valign="middle">42<br>
</td>
<td align="center" valign="middle">39<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Abnormal lymphocytes count <br>
</td>
<td align="center" valign="middle">78<br>
</td>
<td align="center" valign="middle">72<br>
</td>
<td align="center" valign="middle">27<br>
</td>
<td align="center" valign="middle">25<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Pain <br>
</td>
<td align="center" valign="middle">45<br>
</td>
<td align="center" valign="middle">41<br>
</td>
<td align="center" valign="middle">44<br>
</td>
<td align="center" valign="middle">39<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Abnormal platelet count <br>
</td>
<td align="center" valign="middle">43<br>
</td>
<td align="center" valign="middle">39<br>
</td>
<td align="center" valign="middle">8<br>
</td>
<td align="center" valign="middle">7<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Abnormal alkaline phosphatase <br>
</td>
<td align="center" valign="middle">41<br>
</td>
<td align="center" valign="middle">37<br>
</td>
<td align="center" valign="middle">42<br>
</td>
<td align="center" valign="middle">38<br>
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span>/fatigue <br>
</td>
<td align="center" valign="middle">37<br>
</td>
<td align="center" valign="middle">34<br>
</td>
<td align="center" valign="middle">16<br>
</td>
<td align="center" valign="middle">14<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Hyperglycemia <br>
</td>
<td align="center" valign="middle">33<br>
</td>
<td align="center" valign="middle">31<br>
</td>
<td align="center" valign="middle">32<br>
</td>
<td align="center" valign="middle">30<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Edema <br>
</td>
<td align="center" valign="middle">31<br>
</td>
<td align="center" valign="middle">30<br>
</td>
<td align="center" valign="middle">15<br>
</td>
<td align="center" valign="middle">14<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Nausea <br>
</td>
<td align="center" valign="middle">28<br>
</td>
<td align="center" valign="middle">26<br>
</td>
<td align="center" valign="middle">9<br>
</td>
<td align="center" valign="middle">8<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Anorexia <br>
</td>
<td align="center" valign="middle">24<br>
</td>
<td align="center" valign="middle">22<br>
</td>
<td align="center" valign="middle">16<br>
</td>
<td align="center" valign="middle">14<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Abnormal BUN <br>
</td>
<td align="center" valign="middle">24<br>
</td>
<td align="center" valign="middle">22<br>
</td>
<td align="center" valign="middle">22<br>
</td>
<td align="center" valign="middle">20<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Abnormal Transaminase <br>
</td>
<td align="center" valign="middle">22<br>
</td>
<td align="center" valign="middle">20<br>
</td>
<td align="center" valign="middle">16<br>
</td>
<td align="center" valign="middle">14<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Alopecia <br>
</td>
<td align="center" valign="middle">20<br>
</td>
<td align="center" valign="middle">20<br>
</td>
<td align="center" valign="middle">1<br>
</td>
<td align="center" valign="middle">1<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Abnormal Cardiac function <br>
</td>
<td align="center" valign="middle">19<br>
</td>
<td align="center" valign="middle">18<br>
</td>
<td align="center" valign="middle">0<br>
</td>
<td align="center" valign="middle">0<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Infection <br>
</td>
<td align="center" valign="middle">18<br>
</td>
<td align="center" valign="middle">17<br>
</td>
<td align="center" valign="middle">4<br>
</td>
<td align="center" valign="middle">4<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Weight loss <br>
</td>
<td align="center" valign="middle">18<br>
</td>
<td align="center" valign="middle">17<br>
</td>
<td align="center" valign="middle">13<br>
</td>
<td align="center" valign="middle">12<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Dyspnea <br>
</td>
<td align="center" valign="middle">16<br>
</td>
<td align="center" valign="middle">15<br>
</td>
<td align="center" valign="middle">9<br>
</td>
<td align="center" valign="middle">8<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Diarrhea <br>
</td>
<td align="center" valign="middle">16<br>
</td>
<td align="center" valign="middle">14<br>
</td>
<td align="center" valign="middle">4<br>
</td>
<td align="center" valign="middle">4<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Fever in absence of infection <br>
</td>
<td align="center" valign="middle">15<br>
</td>
<td align="center" valign="middle">14<br>
</td>
<td align="center" valign="middle">7<br>
</td>
<td align="center" valign="middle">6<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Weight gain <br>
</td>
<td align="center" valign="middle">15<br>
</td>
<td align="center" valign="middle">14<br>
</td>
<td align="center" valign="middle">16<br>
</td>
<td align="center" valign="middle">15<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Abnormal creatinine <br>
</td>
<td align="center" valign="middle">14<br>
</td>
<td align="center" valign="middle">13<br>
</td>
<td align="center" valign="middle">11<br>
</td>
<td align="center" valign="middle">10<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Other gastrointestinal <br>
</td>
<td align="center" valign="middle">13<br>
</td>
<td align="center" valign="middle">14<br>
</td>
<td align="center" valign="middle">11<br>
</td>
<td align="center" valign="middle">11<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Vomiting <br>
</td>
<td align="center" valign="middle">12<br>
</td>
<td align="center" valign="middle">11<br>
</td>
<td align="center" valign="middle">6<br>
</td>
<td align="center" valign="middle">5<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Other neurologic <br>
</td>
<td align="center" valign="middle">11<br>
</td>
<td align="center" valign="middle">11<br>
</td>
<td align="center" valign="middle">5<br>
</td>
<td align="center" valign="middle">5<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Hypocalcemia <br>
</td>
<td align="center" valign="middle">10<br>
</td>
<td align="center" valign="middle">10<br>
</td>
<td align="center" valign="middle">5<br>
</td>
<td align="center" valign="middle">5<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Hematuria <br>
</td>
<td align="center" valign="middle">9<br>
</td>
<td align="center" valign="middle">11<br>
</td>
<td align="center" valign="middle">5<br>
</td>
<td align="center" valign="middle">6<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Hyponatremia <br>
</td>
<td align="center" valign="middle">9<br>
</td>
<td align="center" valign="middle">9<br>
</td>
<td align="center" valign="middle">3<br>
</td>
<td align="center" valign="middle">3<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Sweats <br>
</td>
<td align="center" valign="middle">9<br>
</td>
<td align="center" valign="middle">9<br>
</td>
<td align="center" valign="middle">2<br>
</td>
<td align="center" valign="middle">2<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Other liver <br>
</td>
<td align="center" valign="middle">8<br>
</td>
<td align="center" valign="middle">8<br>
</td>
<td align="center" valign="middle">8<br>
</td>
<td align="center" valign="middle">8<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Stomatitis <br>
</td>
<td align="center" valign="middle">8<br>
</td>
<td align="center" valign="middle">8<br>
</td>
<td align="center" valign="middle">1<br>
</td>
<td align="center" valign="middle">1<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Cardiac dysrhythmia <br>
</td>
<td align="center" valign="middle">7<br>
</td>
<td align="center" valign="middle">7<br>
</td>
<td align="center" valign="middle">3<br>
</td>
<td align="center" valign="middle">3<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Hypokalemia <br>
</td>
<td align="center" valign="middle">7<br>
</td>
<td align="center" valign="middle">7<br>
</td>
<td align="center" valign="middle">4<br>
</td>
<td align="center" valign="middle">4<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Neuro/constipation <br>
</td>
<td align="center" valign="middle">7<br>
</td>
<td align="center" valign="middle">7<br>
</td>
<td align="center" valign="middle">2<br>
</td>
<td align="center" valign="middle">2<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Neuro/motor disorder<br>
</td>
<td align="center" valign="middle">7<br>
</td>
<td align="center" valign="middle">7<br>
</td>
<td align="center" valign="middle">3<br>
</td>
<td align="center" valign="middle">3<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Neuro/mood disorder<br>
</td>
<td align="center" valign="middle">6<br>
</td>
<td align="center" valign="middle">6<br>
</td>
<td align="center" valign="middle">2<br>
</td>
<td align="center" valign="middle">2<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Skin disorder<br>
</td>
<td align="center" valign="middle">6<br>
</td>
<td align="center" valign="middle">6<br>
</td>
<td align="center" valign="middle">4<br>
</td>
<td align="center" valign="middle">4<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Cardiac ischemia <br>
</td>
<td align="center" valign="middle">5<br>
</td>
<td align="center" valign="middle">5<br>
</td>
<td align="center" valign="middle">1<br>
</td>
<td align="center" valign="middle">1<br>
</td>
</tr>
<tr>
<td align="left" valign="bottom">Chills <br>
</td>
<td align="center" valign="middle">5<br>
</td>
<td align="center" valign="middle">5<br>
</td>
<td align="center" valign="middle">0<br>
</td>
<td align="center" valign="middle">0<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Hemorrhage <br>
</td>
<td align="center" valign="top">5<br>
</td>
<td align="center" valign="top">5<br>
</td>
<td align="center" valign="top">3<br>
</td>
<td align="center" valign="top">3<br>
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgias</span>/arthralgias <br>
</td>
<td align="center" valign="top">5<br>
</td>
<td align="center" valign="top">5<br>
</td>
<td align="center" valign="top">3<br>
</td>
<td align="center" valign="top">3<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Other kidney/bladder <br>
</td>
<td align="center" valign="top">5<br>
</td>
<td align="center" valign="top">5<br>
</td>
<td align="center" valign="top">3<br>
</td>
<td align="center" valign="top">3<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Other endocrine <br>
</td>
<td align="center" valign="top">5<br>
</td>
<td align="center" valign="top">6<br>
</td>
<td align="center" valign="top">3<br>
</td>
<td align="center" valign="top">4<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Other pulmonary <br>
</td>
<td align="center" valign="top">5<br>
</td>
<td align="center" valign="top">5<br>
</td>
<td align="center" valign="top">3<br>
</td>
<td align="center" valign="top">3<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Hypertension <br>
</td>
<td align="center" valign="top">4<br>
</td>
<td align="center" valign="top">4<br>
</td>
<td align="center" valign="top">5<br>
</td>
<td align="center" valign="top">5<br>
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span>/libido <br>
</td>
<td align="center" valign="top">4<br>
</td>
<td align="center" valign="top">7<br>
</td>
<td align="center" valign="top">2<br>
</td>
<td align="center" valign="top">3<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Proteinuria <br>
</td>
<td align="center" valign="top">4<br>
</td>
<td align="center" valign="top">6<br>
</td>
<td align="center" valign="top">2<br>
</td>
<td align="center" valign="top">3<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Sterility <br>
</td>
<td class="Botrule" align="center" valign="top">3<br>
</td>
<td class="Botrule" align="center" valign="top">5<br>
</td>
<td class="Botrule" align="center" valign="top">2<br>
</td>
<td class="Botrule" align="center" valign="top">3<br>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section">
<a name="ID124"></a><a name="section-7.4"></a><p></p>
<h2>General</h2>
<div class="Section">
<a name="ID125"></a><a name="section-7.4.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reaction</span></h3>
<p class="First"><a name="ID126"></a><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> have been reported occasionally. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have been reported rarely. </p>
</div>
<div class="Section">
<a name="ID127"></a><a name="section-7.4.2"></a><p></p>
<h3>Cutaneous</h3>
<p class="First"><a name="ID128"></a><span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> at the infusion site has been reported, which may result in <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, burning, and/or blue discoloration of the skin. <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> can result in tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> with resultant need for debridement and skin grafting. <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span> has also been reported at the site of the infusion.</p>
</div>
<div class="Section">
<a name="ID129"></a><a name="section-7.4.3"></a><p></p>
<h3>Hematologic</h3>
<p class="First"><a name="ID130"></a>Topoisomerase II inhibitors, including MitoXANTRONE Injection, in combination with other antineoplastic agents or alone, have been associated with the development of <span class="product-label-link" type="condition" conceptid="138708" conceptname="Acute leukemia">acute leukemia</span> (see <span class="Bold"><a href="#ID79">WARNINGS</a></span>). </p>
</div>
<div class="Section">
<a name="ID131"></a><a name="section-7.4.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span></h3>
<p class="First"><a name="ID132"></a><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> is rapid in onset and is consistent with the requirement to produce significant <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">marrow hypoplasia</span> in order to achieve a response in <span class="product-label-link" type="condition" conceptid="138708" conceptname="Acute leukemia">acute leukemia</span>. The incidences of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> seen in the U.S. trial are consistent with those reported for other standard induction regimens. </p>
</div>
<div class="Section">
<a name="ID133"></a><a name="section-7.4.5"></a><p></p>
<h3>Hormone-Refractory Prostate Cancer</h3>
<p class="First"><a name="ID134"></a>In a randomized study where dose escalation was required for neutrophil counts greater than 1000/mm<span class="Sup">3</span>, Grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (ANC &lt; 500 /mm<span class="Sup">3</span>) was observed in 54% of patients treated with MitoXANTRONE Injection + low-dose prednisone. In a separate randomized trial where patients were treated with 14 mg/m<span class="Sup">2</span>, Grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> in 23% of patients treated with MitoXANTRONE Injection + hydrocortisone was observed. <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Neutropenic fever</span>/<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> occurred in 11% and 10% of patients receiving MitoXANTRONE Injection + corticosteroids, respectively, on the two trials. Platelets &lt; 50,000/mm<span class="Sup">3 </span>were noted in 4% and 3% of patients receiving MitoXANTRONE Injection + corticosteroids on these trials, and there was one patient <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> on MitoXANTRONE Injection + hydrocortisone due to <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> after a <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span>. </p>
</div>
<div class="Section">
<a name="ID135"></a><a name="section-7.4.6"></a><p></p>
<h3>Gastrointestinal</h3>
<p class="First"><a name="ID136"></a><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> occurred acutely in most patients and may have contributed to reports of <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, but were generally mild to moderate and could be controlled through the use of antiemetics. <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span>/<span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span> occurred within 1 week of therapy. </p>
</div>
<div class="Section">
<a name="ID137"></a><a name="section-7.4.7"></a><p></p>
<h3>Cardiovascular</h3>
<p class="First"><a name="ID138"></a><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, EKG changes including <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, and asymptomatic decreases in left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> have occurred. (See <span class="Bold"><a href="#ID79">WARNINGS</a></span>) </p>
</div>
<div class="Section">
<a name="ID139"></a><a name="section-7.4.8"></a><p></p>
<h3>Pulmonary</h3>
<p class="First"><a name="ID140"></a><span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial pneumonitis</span> has been reported in cancer patients receiving combination chemotherapy that included MitoXANTRONE Injection. </p>
<p>To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID141"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><a name="ID142"></a>There is no known specific antidote for MitoXANTRONE Injection. Accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> have been reported. Four patients receiving 140 to 180 mg/m<span class="Sup">2 </span>as a single bolus injection died as a result of severe <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> with <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Hematologic support and antimicrobial therapy may be required during <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> of severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>. </p>
<p>Although patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> have not been studied, MitoXANTRONE Injection is extensively tissue bound and it is unlikely that the therapeutic effect or toxicity would be mitigated by peritoneal or hemodialysis. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID143"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><a name="ID144"></a>(See also <span class="Bold"><a href="#ID79">WARNINGS</a></span>) </p>
<div class="Section">
<a name="ID145"></a><a name="section-9.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">Multiple Sclerosis</span></h2>
<p class="First"><a name="ID146"></a>The recommended dosage of MitoXANTRONE Injection is 12 mg/m<span class="Sup">2 </span>given as a short (approximately 5 to 15 minutes) intravenous infusion every 3 months. Left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> (LVEF) should be evaluated by echocardiogram or MUGA prior to administration of the initial dose of MitoXANTRONE Injection and all subsequent doses. In addition, LVEF evaluations are recommended if signs or symptoms of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> develop at any time during treatment with MitoXANTRONE Injection. MitoXANTRONE Injection should not be administered to <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> patients with an LVEF &lt;50%, with a clinically significant reduction in LVEF, or to those who have received a cumulative lifetime dose of ≥140 mg/m<span class="Sup">2</span>. Complete blood counts, including platelets, should be monitored prior to each course of MitoXANTRONE Injection and in the event that signs or symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> develop. MitoXANTRONE Injection generally should not be administered to <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> patients with neutrophil counts less than 1500 cells/mm<span class="Sup">3</span>. Liver function tests should also be monitored prior to each course. MitoXANTRONE Injection therapy in <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> patients with <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span> is not recommended because MitoXANTRONE Injection clearance is reduced by <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and no laboratory measurement can predict drug clearance and dose adjustments. </p>
<p>Women with <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> who are biologically capable of becoming pregnant, even if they are using birth control, should have a pregnancy test, and the results should be known, before receiving each dose of MitoXANTRONE Injection (see <span class="Bold"><a href="#ID91">WARNINGS, Pregnancy</a></span>). </p>
</div>
<div class="Section">
<a name="ID147"></a><a name="section-9.2"></a><p></p>
<h2>Hormone-Refractory Prostate Cancer</h2>
<p class="First"><a name="ID148"></a>Based on data from two Phase 3 comparative trials of MitoXANTRONE Injection plus corticosteroids versus corticosteroids alone, the recommended dosage of MitoXANTRONE Injection is 12 to 14 mg/m<span class="Sup">2 </span>given as a short intravenous infusion every 21 days. </p>
</div>
<div class="Section">
<a name="ID149"></a><a name="section-9.3"></a><p></p>
<h2>Combination Initial Therapy for ANLL in Adults</h2>
<p class="First"><a name="ID150"></a>For induction, the recommended dosage is 12 mg/m<span class="Sup">2 </span>of MitoXANTRONE Injection daily on Days 1to 3 given as an intravenous infusion, and 100 mg/m<span class="Sup">2 </span>of cytarabine for 7 days given as a continuous 24-hour infusion on Days 1to7. </p>
<p>                                       </p>
<p>Most complete remissions will occur following the initial course of induction therapy. In the event of an incomplete antileukemic response, a second induction course may be given. MitoXANTRONE Injection should be given for 2 days and cytarabine for 5 days using the same daily dosage levels. </p>
<p>If severe or life-threatening nonhematologic toxicity is observed during the first induction course, the second induction course should be withheld until toxicity resolves. </p>
<p>Consolidation therapy which was used in two large randomized multicenter trials consisted of MitoXANTRONE Injection, 12 mg/m<span class="Sup">2 </span>given by intravenous infusion daily on Days 1 and 2 and cytarabine, 100 mg/m<span class="Sup">2 </span>for 5 days given as a continuous 24-hour infusion on Days 1to 5. The first course was given approximately 6 weeks after the final induction course; the second was generally administered 4 weeks after the first. Severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> occurred. (See <span class="Bold"><a href="#ID45">CLINICAL PHARMACOLOGY</a></span>) </p>
</div>
<div class="Section">
<a name="ID151"></a><a name="section-9.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First"><a name="ID152"></a>For patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, there is at present no laboratory measurement that allows for dose adjustment recommendations. (See <span class="Bold"><a href="#ID52">CLINICAL PHARMACOLOGY, Special Populations, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></span>). </p>
</div>
<div class="Section">
<a name="ID153"></a><a name="section-9.5"></a><p></p>
<h2>Preparation and Administration Precautions</h2>
<p class="First"><a name="ID154"></a><span class="Bold"><span class="Underline">MitoXANTRONE INJECTION CONCENTRATE MUST BE DILUTED PRIOR TO USE</span>. </span></p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. </p>
<p>The dose of MitoXANTRONE Injection should be diluted to at least 50 mL with either 0.9% Sodium Chloride Injection (USP) or 5% Dextrose Injection (USP). MitoXANTRONE Injection may be further diluted into Dextrose 5% in Water, Normal Saline or Dextrose 5% with Normal Saline and used immediately. DO NOT FREEZE. </p>
<p>MitoXANTRONE Injection should not be mixed in the same infusion as heparin since a precipitate may form. Because specific compatibility data are not available, it is recommended that MitoXANTRONE Injection not be mixed in the same infusion with other drugs. The diluted solution should be introduced slowly into the tubing as a freely running intravenous infusion of 0.9% Sodium Chloride Injection (USP) or 5% Dextrose Injection (USP) over a period of not less than 3 minutes. Unused infusion solutions should be discarded immediately in an appropriate fashion. In the case of multidose use, after penetration of the stopper, the remaining portion of the undiluted MitoXANTRONE Injection concentrate should be stored not longer than 7 days between 20°to 25°C (68°to 77°F) or 14 days under refrigeration. DO NOT FREEZE. CONTAINS NO PRESERVATIVE. </p>
<p>Care in the administration of MitoXANTRONE Injection will reduce the chance of <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>. MitoXANTRONE Injection should be administered into the tubing of a freely running intravenous infusion of 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP. The tubing should be attached to a Butterfly needle or other suitable device and inserted preferably into a large vein. If possible, avoid veins over joints or in extremities with compromised venous or lymphatic drainage. Care should be taken to avoid <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> at the infusion site and to avoid contact of MitoXANTRONE Injection with the skin, mucous membranes, or eyes. MitoXANTRONE Injection SHOULD NOT BE ADMINISTERED SUBCUTANEOUSLY. If any signs or symptoms of <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> have occurred, including burning, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, pruritis, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, blue discoloration, or ulceration, the injection or infusion should be immediately terminated and restarted in another vein. During intravenous administration of MitoXANTRONE Injection <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> may occur with or without an accompanying <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> or <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span> even if blood returns well on <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> of the infusion needle. If it is known or suspected that subcutaneous <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> has occurred, it is recommended that intermittent ice packs be placed over the area of <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> and that the affected extremity be elevated. Because of the progressive nature of <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> reactions, the area of injection should be frequently examined and surgery consultation obtained early if there is any sign of a local reaction. </p>
<p>Skin accidentally exposed to MitoXANTRONE Injection should be rinsed copiously with warm water and if the eyes are involved, standard irrigation techniques should be used immediately. The use of goggles, gloves, and protective gowns is recommended during preparation and administration of the drug. </p>
<p>Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published.<span class="Sup">1to 4 </span>There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate. </p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="ID155"></a><a name="section-10"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165. </li>
<li>OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. <span class="Underline">http://www.osha.gov/dts/osta/otm_vi_2.html.</span> </li>
<li>American Society of Health-System Pharmacists. (2006) ASHP Guidelines on Handling Hazardous Drugs. </li>
<li>Polovich, M., White, J.M., &amp; Kelleher, L.O. (eds.) 2005. Chemotherapy and biotherapy guidelines and recommendations for practice (2<span class="Sup">nd </span>ed.) Pittsburgh, PA: Oncology Nursing Society. </li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID157"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><a name="ID158"></a>MitoXANTRONE Injection USP (Concentrate) is a sterile aqueous solution containing mitoxantrone hydrochloride at a concentration equivalent to 2 mg mitoxantrone free base per mL supplied in vials for multidose use as follows:  </p>
<p>NDC 0069- 0080 -01 – <span class="Bold">20 mg/10 mL/multidose vial (2 mg/mL) </span></p>
<p>MitoXANTRONE Injection USP (Concentrate) should be stored between 20°to 25°C (68°to77°F). DO NOT FREEZE.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID159"></a><a name="section-12"></a><p></p>
<div class="Figure"><img alt="pfizer-logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c101cb05-faaa-44cb-9666-c8214628c844&amp;name=mitoxan-inj-pfizer-figure-02.jpg"></div>
<p class="First"><a name="ID160"></a>Distributed by: </p>
<p>Pfizer Labs</p>
<p>Division of Pfizer Inc, New York, NY 10017</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="ID218"></a><a name="section-13"></a><p></p>
<h1>Medication Guide</h1>
<p class="First"><a name="ID219"></a><span class="Bold">MitoXANTRONE Injection USP (Concentrate) </span></p>
<p><span class="Bold">(pronounced as mito-xan-trone)</span></p>
<p>CONTAINS SODIUM METABISULPHITE, A SULPHITE THAT MAY CAUSE ALLERGIC-TYPE REACTIONS INCLUDING ANAPHYLACTIC SYMPTOMS AND LIFE-THREATENING OR LESS SEVERE <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">ASTHMATIC</span> EPISODES IN CERTAIN SUSCEPTIBLE PEOPLE. THE OVERALL PREVALENCE OF SULFITE SENSITIVITY IN THE GENERAL POPULATION IS UNKNOWN AND PROBABLY LOW. SULFITE SENSITIVITY IS SEEN MORE FREQUENTLY IN <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">ASTHMATIC</span> THAN IN NONASTHMATIC PEOPLE.</p>
<p>Read this Medication Guide before you start receiving mitoXANTRONE and each time you receive mitoXANTRONE. There may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment.</p>
<p><span class="Bold">What is the most important information I should know about mitoXANTRONE? </span></p>
<p><span class="Bold">MitoXANTRONE can cause serious side effects, including:</span></p>
<ul class="Disc"><li>
<span class="Bold">decrease in the ability of your bone marrow to      make blood cells   (<span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>). </span> Your doctor may do blood tests      during treatment with mitoXANTRONE to check your blood cell counts. The      symptoms of <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> can include: </li></ul>
<ol>
<li>feeling tired </li>
<li>increased <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> </li>
<li><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> easily </li>
</ol>
<ul class="Disc"><li>  <span class="Bold">heart problems (<span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>) that may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> even in people who have never had heart problems before. </span> <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span> can happen while you receive mitoXANTRONE, or months to years after you stop receiving mitoXANTRONE. Your risk of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> increases the more mitoXANTRONE you receive. </li></ul>
<p><a name="ID226"></a>Call your doctor or get medical help right away if you have any of these problems during or after treatment with mitoXANTRONE:</p>
<ol>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your ankles or feet </li>
<li>sudden <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> </li>
<li>fast heartbeat or pounding in your chest </li>
</ol>
<p><a name="ID224"></a><span class="Bold">Before receiving mitoXANTRONE for the first time, you should have the </span></p>
<p><span class="Bold">following tests done: </span></p>
<ol>
<li>physical examination </li>
<li>a test to check your heart's electrical activity (electrocardiogram) </li>
<li>a test to check your heart's ability to pump blood </li>
</ol>
<p><a name="ID227"></a><span class="Bold">If you receive mitoXANTRONE to treat <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">Multiple Sclerosis</span> (MS), your doctor should also do the tests above: </span></p>
<ol>
<li>before you receive each mitoXANTRONE dose </li>
<li>yearly after you stop receiving mitoXANTRONE treatment </li>
</ol>
<ul class="Disc"><li>
<span class="Bold">acute      <span class="product-label-link" type="condition" conceptid="135499" conceptname="Subacute myeloid leukemia">myeloid leukemia</span> (AML). </span> Receiving      mitoXANTRONE increases your risk of AML. AML is a cancer of the      blood-forming cells of your bone marrow. Symptoms of AML can include:</li></ul>
<ol>
<li>feeling unusually tired and weak </li>
<li>increased <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> </li>
<li><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> easily </li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your bones </li>
<li>trouble breathing </li>
<li>unexplained <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">night sweats</span> </li>
</ol>
<ul class="Disc"><li>
<span class="Bold">skin problems at your injection site. If      mitoXANTRONE leaks out of your vein, skin problems can happen that may      lead to serious skin damage (<span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>). <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">Necrosis</span> may need to be repaired      surgically. </span> Tell your doctor right away if you have any of the      following problems at your injection site: </li></ul>
<ol>
<li><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> </li>
<li>burning </li>
<li>skin turns a bluish color </li>
</ol>
<p><a name="ID233"></a><span class="Bold">What is mitoXANTRONE? </span></p>
<p>MitoXANTRONE is a prescription medicine used alone or with other medicines to treat people with: </p>
<ul class="Disc">
<li>secondary (chronic) progressive, progressive relapsing, or worsening relapsing-</li>
<li>remitting <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> (MS) </li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> related to advanced hormone-refractory prostate cancer </li>
<li>acute   nonlymphocytic <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> (ANLL) </li>
</ul>
<p><a name="ID235"></a>MitoXANTRONE is not for people with primary progressive MS. </p>
<p>It is not known if mitroXANTRONE is safe and effective in children. </p>
<p><span class="Bold">Who should not receive mitoXANTRONE? </span></p>
<p><span class="Bold">Do not receive mitoXANTRONE if you </span>are allergic to mitoXANTRONE or any of the ingredients in mitoXATRONE. See the end of this Medication Guide for a complete list of ingredients in mitoXATRONE. </p>
<p><span class="Bold">What should I tell my doctor before receiving mitoXANTRONE? Before you receive mitoXANTRONE, tell your doctor if you have: </span></p>
<ul class="Disc">
<li>received mitoXANTRONE in the past </li>
<li>heart problems </li>
<li>liver problems </li>
<li>kidney problems </li>
<li>low blood cell counts </li>
<li>an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> </li>
<li>had radiation treatment in your chest area </li>
<li>any other medical conditions </li>
<li>
<span class="Bold">are pregnant or plan to become pregnant. </span> MitoXANTRONE may harm your unborn baby. Women who are able to become pregnant should use effective birth control (contraception) while using mitoXANTRONE and should have a pregnancy test, with known results, before receiving each dose of mitoXANTRONE. Talk to your doctor about using effective birth control while you receive mitoXANTRONE.</li>
<li>
<span class="Bold">are breastfeeding or plan to breastfeed. </span> MitoXANTRONE can pass into your breast milk and may harm your baby. Talk to your doctor about the best way to feed your baby if you receive mitoXANTRONE. Do not breastfeed while receiving mitoXANTRONE.</li>
</ul>
<p><a name="ID237"></a><span class="Bold">Tell your doctor about all the medicines you take, </span>including prescription and nonprescription medicines, vitamins, and herbal supplements. </p>
<p>Using mitoXANTRONE with certain other medicines may cause serious side effects. </p>
<p>Especially tell your doctor if you take or have taken: </p>
<ul class="Disc">
<li>medicines      for cancer treatment called anthracyclines or anthracenediones </li>
<li>medicines      that may affect your heart </li>
</ul>
<p><a name="ID239"></a>Ask your doctor or pharmacist for a list of these medicines if you are not sure if you take or have taken any of these medicines. </p>
<p>Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I receive mitoXANTRONE? </span></p>
<ul class="Disc">
<li>MitoXANTRONE      is given by slow infusion through a needle placed in a vein (intravenous      infusion) in your arm. </li>
<li>Your      doctor will tell you how often you will receive mitoXANTRONE. </li>
<li>If      you receive mitoXANTRONE to treat MS, your doctor should check how well      your heart is working before each mitoXANTRONE dose. Talk to your doctor      if you have not had your heart tests done before your mitoXANTRONE dose. </li>
<li>Your doctor will do blood tests during your treatment      with mitoXANTRONE to check your blood cell counts.</li>
<li>If you are a woman of childbearing age taking      mitoXANTRONE to treat MS, your doctor should do a pregnancy test before      each mitoXANTRONE dose, even if you are using birth control. </li>
<li>If you receive mitoXANTRONE to treat MS, there is a      limit to the total amount of mitoXANTRONE you can receive during your      lifetime. There is a higher risk of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> with increasing total      lifetime doses of mitoXANTRONE.</li>
</ul>
<p><a name="ID241"></a><span class="Bold">What are the possible side effects of mitoXANTRONE? </span></p>
<p><span class="Bold">MitoXANTRONE may cause serious side effects, including: </span></p>
<ul class="Disc"><li>
<span class="Bold">See "What is the most important information I      should know about mitoXANTRONE?" </span> </li></ul>
<p><a name="ID243"></a>The most common side effects of mitoXANTRONE include: </p>
<ul class="Disc">
<li>blue-green      colored urine for about 24 hours after receiving mitoXANTRONE. This color      change is harmless. </li>
<li>bluish      coloring of the whites of your eyes for about 24 hours after receiving mitoXANTRONE.      This color change is harmless. </li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>      </li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>      </li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>      </li>
<li>stomach      <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> </li>
<li>hair      loss </li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>      and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> due to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> </li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>      and <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span> due to <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span> </li>
<li>mouth      sores due to mouth <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> </li>
<li>loss      of your menstrual period </li>
</ul>
<p><a name="ID245"></a>Tell your doctor if you have any side effect that bothers you or that does not go away. </p>
<p>These are not all the possible side effects of mitoXANTRONE. For more information, ask your doctor or pharmacist. </p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </p>
<p><span class="Bold">General information about the safe and effective use of mitoXANTRONE. </span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. </p>
<p>This Medication Guide summarizes the most important information about mitoXANTRONE. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about mitoXANTRONE that is written for health professionals. </p>
<p>For more information, call Pfizer at 1-800-438-1985. </p>
<p><span class="Bold">What are the ingredients in mitoXANTRONE? </span></p>
<p>Active ingredient: mitoXANTRONE hydrochloride </p>
<p>Inactive ingredients: sodium chloride, sodium acetate, Sodium Metabisulphite and acetic acid </p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<div class="Figure"><img alt="pfizer-logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c101cb05-faaa-44cb-9666-c8214628c844&amp;name=mitoxan-inj-pfizer-figure-03.jpg"></div>
<p><a name="ID247"></a>Distributed by: </p>
<p>Pfizer Labs</p>
<p>Division of Pfizer Inc, New York, NY 10017</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID212"></a><a name="section-14"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><a name="ID213"></a>Rx Only</p>
<p>10 mL-Multi-Doses Vial</p>
<p>Mitoxantrone Injection USP (Concentrate)</p>
<p>20mg/10mL (2mg/mL)</p>
<p>Each patient should receive the enclosed Medication guide</p>
<p>For Intravenous Infusion</p>
<p>After Dilution</p>
<p>Cytotoxic Agent</p>
<p>Sterile</p>
<div class="Figure"><img alt="vial-label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c101cb05-faaa-44cb-9666-c8214628c844&amp;name=mitoxan-inj-pfizer-figure-04.jpg"></div>
<p><a name="ID215"></a>Rx Only</p>
<p>10 mL-Multi-Doses Vial</p>
<p>Mitoxantrone Injection USP (Concentrate)</p>
<p>20mg/10mL (2mg/mL)</p>
<p>Each patient should receive the enclosed Medication guide</p>
<p>For Intravenous Infusion</p>
<p>After Dilution</p>
<p>Cytotoxic Agent</p>
<p>      Sterile</p>
<div class="Figure"><img alt="carton-label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c101cb05-faaa-44cb-9666-c8214628c844&amp;name=mitoxan-inj-pfizer-figure-05.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MITOXANTRONE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">mitoxantrone hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-0080</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MITOXANTRONE HYDROCHLORIDE</strong> (MITOXANTRONE) </td>
<td class="formItem">MITOXANTRONE</td>
<td class="formItem">2 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ACETIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM ACETATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM METABISULFITE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-0080-01</td>
<td class="formItem">10 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA201014</td>
<td class="formItem">12/12/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Pfizer Laboratories Div Pfizer Inc.
							(134489525)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Onco Therapies Limited  (676159830)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Onco Therapies Limited </td>
<td class="formItem"></td>
<td class="formItem">676159830</td>
<td class="formItem">Analysis(0069-0080), Manufacture(0069-0080), Sterilize(0069-0080), Pack(0069-0080)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5815a273-349f-4a9b-b6fd-af44958ba67c</div>
<div>Set id: c101cb05-faaa-44cb-9666-c8214628c844</div>
<div>Version: 1</div>
<div>Effective Time: 20130515</div>
</div>
</div> <div class="DistributorName">Pfizer Laboratories Div Pfizer Inc.</div></p>
</body></html>
